

# **University of Rochester and Related Entities**

**Reports on Federal Awards in  
Accordance with Uniform Guidance  
For the Year Ended June 30, 2022  
EIN: 16-0743209**

# University of Rochester and Related Entities

## Index

June 30, 2022

---

	Page(s)
<b>Part I – Consolidated Financial Statements and Schedule of Expenditures of Federal Awards</b>	
Report of Independent Auditors .....	1–3
Consolidated Financial Statements and Notes to Financial Statements .....	4–47
Schedule of Expenditures of Federal Awards and Notes to Schedule of Expenditures of Federal Awards .....	48–67
<b>Part II – Reports on Internal Controls and Compliance</b>	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i> .....	68–69
Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance .....	70–72
<b>Part III – Audit Findings and Questioned Costs</b>	
Schedule of Findings and Questioned Costs.....	73-74
Summary Schedule of Prior Audit Findings .....	75-76

**Part I – Consolidated Financial Statements and  
Schedule of Expenditures of Federal Awards**



## Report of Independent Auditors

To the Board of Trustees of the University of Rochester

### Report on the Audit of the Consolidated Financial Statements

#### *Opinion*

We have audited the accompanying consolidated financial statements of the University of Rochester and its related entities (the "University"), which comprise the consolidated balance sheets as of June 30, 2022 and 2021, and the related consolidated statements of activities and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the University as of June 30, 2022 and 2021, and its changes in net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

#### *Basis for Opinion*

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### *Responsibilities of Management for the Consolidated Financial Statements*

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for one year after the date the consolidated financial statements are issued.



### ***Auditors' Responsibilities for the Audit of the Consolidated Financial Statements***

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS and *Government Auditing Standards*, will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with US GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

### ***Supplemental Information***

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended June 30, 2022 is presented for purposes of additional analysis as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The



information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

***Other Reporting Required by Government Auditing Standards***

In accordance with *Government Auditing Standards*, we have also issued our report dated October 26, 2022 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2022. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control over financial reporting and compliance.

*PricewaterhouseCoopers LLP*

Fairport, New York  
October 26, 2022

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Consolidated Balance Sheets**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

	<u>2022</u>	<u>2021</u>
<b>Assets</b>		
Cash and cash equivalents	\$ 836,577	\$ 889,136
Short-term investments	868,278	892,621
Accounts receivable, net	558,452	554,640
Inventories, prepaid expenses, and deferred charges	108,420	106,749
Contributions receivable, net	79,094	81,774
Notes receivable, net	13,899	15,377
Other assets	79,513	82,180
Investments held for long-term purposes	3,218,567	3,822,792
Property, plant and equipment, net	2,439,597	2,308,122
Right of use assets	184,425	199,672
Investments in perpetual funds held in trusts by others	61,002	73,039
<b>Total assets</b>	<u><u>\$ 8,447,824</u></u>	<u><u>\$ 9,026,102</u></u>
<b>Liabilities and Net Assets</b>		
Liabilities:		
Accounts payable and accrued expenses	\$ 785,624	\$ 791,853
Deferred revenue	86,002	72,024
Third-party settlements payable, net and other	297,108	399,852
Accrued pension, post-retirement, and post-employment	574,700	701,671
Long-term debt	1,565,561	1,526,692
Lease liabilities	184,320	199,528
Asset retirement obligation	38,615	38,647
Refundable U.S. Government grants for student loans	5,282	7,160
<b>Total liabilities</b>	<u><u>\$ 3,537,212</u></u>	<u><u>\$ 3,737,427</u></u>
Net Assets:		
Without donor restrictions	3,253,796	3,391,881
With donor restrictions	1,656,816	1,896,794
<b>Total net assets</b>	<u><u>4,910,612</u></u>	<u><u>5,288,675</u></u>
<b>Total liabilities and net assets</b>	<u><u>\$ 8,447,824</u></u>	<u><u>\$ 9,026,102</u></u>

The accompanying notes are an integral part of these consolidated financial statements.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES  
Consolidated Statement of Activities  
For The Year Ended June 30, 2022  
(dollars in thousands)**

	<b>Without Donor Restrictions</b>	<b>With Donor Restrictions</b>	<b>Total</b>
<b>Operating revenues and other support:</b>			
Tuition and fees	\$ 318,113	\$ -	\$ 318,113
Grants and contracts	512,416	-	512,416
Gifts and pledges	31,429	72,372	103,801
Hospital and faculty practice patient care	4,279,153	-	4,279,153
Auxiliary enterprises	118,037	-	118,037
Interest income and depreciation of short-term investments	(63,912)	-	(63,912)
Educational activities	18,439	-	18,439
Other sources	68,967	-	68,967
Long-term investment income and gains allocated to operations	118,928	-	118,928
Net assets released from restriction	77,404	(77,404)	-
<b>Total operating revenue and other support</b>	<b>5,478,974</b>	<b>(5,032)</b>	<b>5,473,942</b>
<b>Operating expenses:</b>			
Salaries and wages	2,601,548	-	2,601,548
Fringe benefits	686,737	-	686,737
Total compensation	3,288,285	-	3,288,285
Supplies	1,041,116	-	1,041,116
Business and professional	396,775	-	396,775
Utilities	67,517	-	67,517
Maintenance and facilities costs	186,717	-	186,717
Depreciation	268,244	-	268,244
Interest	43,670	-	43,670
Other	140,241	-	140,241
<b>Total operating expenses</b>	<b>5,432,565</b>	<b>-</b>	<b>5,432,565</b>
<b>Change in net assets from operating activities</b>	<b>46,409</b>	<b>(5,032)</b>	<b>41,377</b>
Non-operating activities:			
Long-term investment activities:			
Investment income	7,832	7,627	15,459
Net depreciation	(167,583)	(244,754)	(412,337)
<b>Total long-term investment activities</b>	<b>(159,751)</b>	<b>(237,127)</b>	<b>(396,878)</b>
Long-term investment income and gains allocated for operations	(118,928)	-	(118,928)
Other changes, net	94,185	(3,343)	90,842
Change in valuation of annuities	-	5,524	5,524
<b>Change in net assets from non-operating activities</b>	<b>(184,494)</b>	<b>(234,946)</b>	<b>(419,440)</b>
Change in net assets	(138,085)	(239,978)	(378,063)
<b>Beginning net assets</b>	<b>3,391,881</b>	<b>1,896,794</b>	<b>5,288,675</b>
<b>Ending net assets</b>	<b>\$ 3,253,796</b>	<b>\$ 1,656,816</b>	<b>\$ 4,910,612</b>

The accompanying notes are an integral part of these consolidated financial statements.



**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Consolidated Statement of Activities**  
**For The Year Ended June 30, 2021**  
**(dollars in thousands)**

	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>	<u>Total</u>
<b>Operating revenues and other support:</b>			
Tuition and fees	\$ 311,435	\$ -	\$ 311,435
Grants and contracts	575,035	-	575,035
Gifts and pledges	21,982	62,417	84,399
Hospital and faculty practice patient care	4,103,766	-	4,103,766
Auxiliary enterprises	94,545	-	94,545
Interest income and appreciation of short-term investments	110,612	-	110,612
Educational activities	14,213	-	14,213
Other sources	68,606	-	68,606
Long-term investment income and gains allocated to operations	114,314	-	114,314
Net assets released from restriction	84,249	(84,249)	-
<b>Total operating revenue and other support</b>	<u>5,498,757</u>	<u>(21,832)</u>	<u>5,476,925</u>
<b>Operating expenses:</b>			
Salaries and wages	2,391,744	-	2,391,744
Fringe benefits	644,225	-	644,225
Total compensation	3,035,969	-	3,035,969
Supplies	967,176	-	967,176
Business and professional	268,044	-	268,044
Utilities	63,953	-	63,953
Maintenance and facilities costs	173,462	-	173,462
Depreciation	265,545	-	265,545
Interest	46,094	-	46,094
Other	116,828	-	116,828
<b>Total operating expenses</b>	<u>4,937,071</u>	<u>-</u>	<u>4,937,071</u>
<b>Change in net assets from operating activities</b>	<u>561,686</u>	<u>(21,832)</u>	<u>539,854</u>
Non-operating activities:			
Long-term investment activities:			
Investment income	6,899	5,746	12,645
Net appreciation	444,989	553,010	997,999
<b>Total long-term investment activities</b>	451,888	558,756	1,010,644
Long-term investment income and gains allocated for operations	(114,314)	-	(114,314)
Loss on extinguishment of debt	(1,211)	-	(1,211)
Other changes, net	24,609	293	24,902
Change in valuation of annuities	-	(13,100)	(13,100)
<b>Change in net assets from non-operating activities</b>	<u>360,972</u>	<u>545,949</u>	<u>906,921</u>
Change in net assets	922,658	524,117	1,446,775
<b>Beginning net assets</b>	2,469,223	1,372,677	3,841,900
<b>Ending net assets</b>	<u>\$ 3,391,881</u>	<u>\$ 1,896,794</u>	<u>\$ 5,288,675</u>

The accompanying notes are an integral part of these consolidated financial statements.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Consolidated Statement of Cash Flows**  
**For The Year Ended June 30, 2022 and 2021**  
**(dollars in thousands)**

	<b>2022</b>	<b>2021</b>
<b>Cash flows from operating activities:</b>		
Change in net assets	\$ (378,063)	\$ 1,446,775
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Depreciation expense	268,244	265,545
Net depreciation (appreciation) on investment activities	466,235	(1,089,003)
Gifts of property, plant, equipment and other	(1,760)	(3,310)
Bond premium amortization	(9,577)	(8,972)
Loss on extinguishment of debt	-	1,211
Loss on disposals of property, plant, and equipment	7,745	3,373
Change in funded status of pension plan	(98,505)	(86,565)
Contributions for long-term investment, net	(75,052)	(72,271)
(Increases)/decreases in:		
Accounts receivable, net	(3,812)	(43,006)
Inventories, prepaid expenses and deferred charges	256	(10,342)
Contributions receivable, net	6,406	13,468
Other assets	(1,440)	(8,797)
Increases/(decreases) in:		
Accounts payable and accrued expenses	(39,116)	109,082
Deferred revenues	13,978	(25,743)
Third-party settlements payable, net and other	(102,744)	11,676
Accrued pension, post-retirement, and post-employment	(28,466)	99,008
Net cash provided by operating activities	24,329	602,129
<b>Cash flows from investing activities:</b>		
Purchases of property, plant and equipment	(373,680)	(248,372)
Purchases of investments	(694,883)	(955,655)
Proceeds from the sale of investments	868,627	449,333
Decrease/(increase) in investments in perpetual trusts held by others	671	(16,156)
Decrease in notes receivable, net	1,478	1,916
Net cash used in investing activities	(197,787)	(768,934)
<b>Cash flows from financing activities:</b>		
Borrowings on lines-of-credit	7,913	689
Payments on lines-of-credit	(4,937)	(23,255)
Payments of long-term debt	(66,208)	(169,843)
Proceeds from issuance of long-term debt	110,589	513,117
Deferred financing costs	368	817
Decrease in refundable U.S. Government grants for student loans	(1,878)	(1,924)
Contributions for long-term investment, net	75,052	72,271
Net cash provided by financing activities	120,899	391,872
<b>Net (decrease)/increase in cash and cash equivalents</b>	<b>(52,559)</b>	<b>225,067</b>
<b>Cash and cash equivalents, beginning of year</b>	<b>889,136</b>	<b>664,069</b>
<b>Cash and cash equivalents, end of year</b>	<b>\$ 836,577</b>	<b>\$ 889,136</b>
<b>Supplemental disclosure of cash flow information:</b>		
Cash paid during the year for interest on long-term debt	\$ 37,795	\$ 31,234
Operating cash flows from lease liabilities	\$ 47,929	\$ 48,333
Increase/(decrease) in construction related payables	\$ 29,905	\$ (5,371)
Right of use assets obtained in exchange for operating leases	\$ 56,450	\$ 30,524
Right of use assets obtained in exchange for finance leases	\$ 3,696	\$ 10,715

The accompanying notes are an integral part of these consolidated financial statements.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

**(1) Summary of Significant Accounting Policies**

---

**(a) General**

The University of Rochester and related entities (the University) is a private not-for-profit institution of higher education based in Rochester, New York. The University provides education and training, primarily for students at the undergraduate, graduate, and postdoctoral levels. It also performs research, training, and other services under grants, contracts, and similar agreements with sponsoring organizations, primarily departments and agencies of the United States Government; and provides health care services through Strong Memorial Hospital, UR Medicine Home Care, Inc., the various entities included in Strong Partners Health System, Inc. (SPHS), F.F. Thompson Health System, Inc., Livingston Health Care System, Inc., The Memorial Hospital of William F. and Gertrude F. Jones, Inc. and St. James Hospital.

**(b) Basis of Presentation**

The accompanying consolidated financial statements include all of the integrated divisions of the University – Arts, Sciences and Engineering (including the Hajim School of Engineering and Applied Sciences), Margaret Warner Graduate School of Education and Human Development, William E. Simon Graduate School of Business Administration, Eastman School of Music, Memorial Art Gallery, School of Medicine and Dentistry, Strong Memorial Hospital, School of Nursing, Eastman Institute for Oral Health, Health Sciences, and University of Rochester Medical Faculty Group. Included also are SPHS, Eastman Dental Center Foundation, Inc., UR Medicine Home Care, Inc., Excell Partners, Inc., Rochester BioVenture Center, Inc., NextCorps, F.F. Thompson Health System, Inc., Accountable Health Partners, LLC., Livingston Health Care System, Inc., The Memorial Hospital of William F. and Gertrude F. Jones, Inc. and St. James Hospital. All interorganizational balances and transactions have been eliminated.

The University is the sole member of SPHS, which is the sole member of Highland Hospital of Rochester (including its subsidiaries: The Highland Foundation, Inc., Highland Facilities Development Corp., and Medical Administrative Associates, Inc.); The Highlands Living Center, Inc.; Highland Community Development Corporation; and The Meadows at Westfall, Inc. Highland Hospital and its subsidiaries have debt outstanding which has been included in the University's consolidated financial statements; however, under the terms of the affiliation agreement with SPHS, the University has no legal obligation for the debt of Highland Hospital of Rochester and its subsidiaries.

The Eastman Dental Center Foundation, Inc. was formed to hold and manage the investment assets of the former Eastman Dental Center. Income and assets of the Foundation are used to support oral health, education, and research projects at the University.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

The University is the sole corporate member of UR Medicine Home Care, Inc. (URMHC), which is the sole corporate member of UR Medicine Home Care, Certified Services, Inc. (URMHCCS) (which is in turn the sole corporate member of Finger Lakes Home Care, Inc.), UR Medicine Home Care, Licensed Services, Inc., UR Medicine Home Care, Community Services, Inc, and UR Medicine Home Care Foundation, Inc. In August 2018, the Board of Directors of URMHC voted to transfer the assets held by URMHC for the benefit of the URMHC affiliates to UR Medicine Home Care Foundation, Inc. As of June 30, 2022, this transfer has not occurred.

The University is the sole corporate member of Excell Partners, Inc., which was formed to support early stage commercial development utilizing technologies created at the University of Rochester and other regional colleges and universities.

The University is the sole corporate member of Rochester BioVenture Center, Inc. (including its subsidiary Excell Technology Ventures, Inc.), which was formed to support the development of new businesses utilizing technologies created at the University and other regional colleges and universities, through the operation of incubator/research facilities in Monroe County, New York. As of June 30, 2022, Rochester BioVenture Center, Inc. is inactive.

The University is the sole corporate member of NextCorps, Inc., which is a not-for-profit economic development organization that promotes the creation and growth of technology companies through support services and incubation facilities and provides consulting services for manufacturers.

The University is the sole corporate member of F.F. Thompson Health System, Inc. (THS) (including its subsidiaries The Frederick Ferris Thompson Hospital (FFT Hospital), M.M. Ewing Continuing Care Center (CCC), F.F.T. Senior Communities, Inc. (FFTSC), FFTH Properties and Services, Inc. (FFTH Properties), and The F.F. Thompson Foundation, Inc. (FFTF). THS remains the sole member of FFT Hospital, CCC, FFTSC, and FFTF and the sole shareholder of FFTH Properties. The University, THS and THS's subsidiaries continue as separate and distinct corporations.

Accountable Health Partners, LLC. (AHP), a New York State limited liability company, was formed in January 2013, partly in response to the Patient Protection and Affordable Care Act of 2010. Through AHP, the members hope to harness the collective expertise of physicians and hospitals to work with third-party payors to provide quality comprehensive and cost-effective patient care to the Greater Rochester New York community. The University has a controlling financial interest through direct and indirect ownership of a majority voting interest in AHP.

The University is the sole corporate member of Livingston Health Care System, Inc. (including Noyes Memorial Hospital and subsidiaries); The Memorial Hospital of William F. and Gertrude F. Jones, Inc., and subsidiaries; and St. James Hospital and subsidiaries.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

**(c) Basis of Accounting and Use of Estimates**

The consolidated financial statements of the University are prepared on the accrual basis of accounting in accordance with generally accepted accounting principles (GAAP) in the United States of America and with the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 958, *Not-for-Profit Entities*. Accordingly, the University classifies resources into two categories based on the existence or absence of donor-imposed restrictions: net assets without donor restrictions and net assets with donor restrictions.

Net Assets Without Donor Restrictions are free of explicit donor-imposed restrictions. All revenues, gains, and losses that are not restricted by donors are included in this classification. All operating expenses are reported as decreases in net assets without donor restrictions.

Net Assets With Donor Restrictions are subject to explicit donor-imposed restrictions that will be met either by actions of the University or the passage of time. These net assets include donor restricted endowments, unconditional pledges, split-interest agreements, and investments in perpetual trusts held by others. Generally, the donor-imposed restrictions of these assets permit the University to use all or part of the income earned on related investments only for certain general or specific purposes.

Expirations of donor restrictions on net assets (i.e. the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from restrictions in the consolidated statements of activities.

Measure of Operations - The University's measure of operations as presented in the consolidated statements of activities includes revenue and expenses related primarily to educational and training programs, research activities, hospital and patient care activities provided by the University and its related entities, unconditional gifts and pledges, the allocation of endowment spending for operations and other revenues.

Nonoperating activities consist primarily of investment income and (depreciation) appreciation from long-term investments in excess of amounts utilized for operations. Other changes, net consists primarily of adjustments in pension, post-retirement, and post-employment obligations based on actuarially determined liabilities.

Use of Estimates - The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosures of contingencies at the dates of the consolidated financial statements and revenues and expenses during the reporting periods. Management's assumptions are primarily related to the appropriate discount rate for the purposes of retirement and post-retirement plan valuations, the inputs utilized in determining the fair value of investments, allowances for doubtful accounts, self-insured risks, and third-party payor contractual adjustments and allowances. Actual results may differ from those estimates.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

**(d) Income Taxes**

The University and the majority of its affiliates are not-for-profit organizations as described in section 501(c)(3) of the Internal Revenue Code and are generally exempt from income taxes on related income pursuant to section 501(a) of the Code. Unrelated activities and income, including certain laboratory and facility rentals and income from limited partnerships in the long-term investment pool, are subject to federal and state unrelated business income tax.

The University regularly evaluates its tax position and does not believe it has any uncertain tax positions that require disclosure or adjustment to the consolidated financial statements based on currently available regulatory guidance.

**(e) Fair Value Measurements**

Fair value measurements reflected in the consolidated financial statements represent the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP provides a hierarchy that prioritizes the inputs to fair value measurements based on the extent to which inputs to valuation techniques are observable in the marketplace. The hierarchy assigns a higher priority to observable inputs that reflect verifiable information obtained from independent sources, and a lower priority to unobservable inputs that would reflect the University's assumptions about how market participants would value an asset or liability based on the best information available. Fair value measurements must maximize the use of observable inputs and minimize the use of unobservable inputs.

The three levels of the hierarchy of inputs used to measure fair value are described briefly as follows:

Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities that are available at the measurement date.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly at the measurement date.

Level 3 - Unobservable inputs for the asset or liability, used in situations in which little or no market activity exists for the asset or liability at the measurement date.

The categorization of fair value measurements by level of the hierarchy is based upon the lowest level input that is significant to the overall fair value measurement for a given asset or liability. In the event that changes in the inputs used in the fair value measurement of an asset or liability result in a transfer of the fair value measurement to a different categorization (e.g., from Level 3 to Level 2), such transfers between fair value categories are recognized at the end of the reporting period.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

The requirement to disclose the hierarchy level does not apply to alternative investments measured at net asset value (NAV). As a practical expedient, the University uses its ownership interest in the NAV to determine the fair value of all alternative investments that do not have a readily determinable fair value, and have financial statements consistent with the measurement principles of an investment company or have the attributes of an investment company. The NAV of these investments is determined by the general partner and is based upon appraisal or other estimates that require judgment. If no public market exists for the investment securities, the general partner will take into consideration, among other things, prices of recent significant transactions of similar securities, and subsequent developments concerning the companies to which the securities relate. The University performs significant due diligence around these investments to ensure that NAV is an appropriate measure of fair value.

**(f) Cash and Cash Equivalents**

Cash and cash equivalents include amounts on deposit with financial institutions; cash equivalents are short-term investments with maturities of three months or less at the time of purchase and other highly liquid investments, primarily cash management funds. Short-term highly liquid investments held within the endowment and similar investment pools are classified as investments rather than cash equivalents and restricted cash is defined as that which is legally restricted to withdrawal and usage. The fair value of cash equivalents has been classified as Level 1 in accordance with the fair value hierarchy.

**(g) Short-Term Investments**

Short-term investments include all other current investments with original maturities greater than three months and are used to support operations. These current investments include obligations of the U.S. Treasury, U.S. Government and other government agencies, and corporate and foreign bonds. Also included are internal operating funds invested in the University's long-term investment pool that may be liquidated upon demand at any time.

**(h) Inventories**

Inventories, primarily pharmaceutical and medical supplies, are valued at the lower of cost or net realizable value, which is determined by the first-in, first-out method, or market.

**(i) Investments Held for Long-Term Purposes**

The University's investments are comprised of the assets of the University's endowment and other investments held for general operating purposes. The University reports investments at fair value as described further in Note 6. Investment expenses are netted against investment return and reported in the same net asset category as investment return.

Investment securities are exposed to various risks, such as interest rates, market, economic conditions, world affairs, and credit risks. Due to the level of risk associated with certain investment securities, it is possible that changes in value could occur in the near term and such changes could materially affect the amounts reported in the investments and investment activity of the University.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

**(j) Endowment**

The University's endowment consists of approximately 2,840 individual endowments established for a variety of purposes including donor-restricted endowment funds and funds designated by the Board of Trustees (Board) to function as endowments. Net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

The Board interprets the New York Prudent Management of Institutional Funds Act (NYPMIFA) to allow for the spending of income and gains on investments of donor restricted endowments in a manner that is prudent, considering such factors as the duration and preservation of the endowment fund, the purposes of the institution and the endowment fund, general economic conditions including the potential effect of inflation or deflation, the expected total return of the fund, other resources of the University, the needs of the University and the fund to make distributions and preserve capital, and the University's investment policy.

Investment of the University's net assets held for endowment and similar purposes is based upon a total return policy, and the utilization of its endowment resources for current operating and capital needs is related to this policy. Although NYPMIFA does not preclude the University from spending below the original gift value of donor restricted endowment funds, the University's policy is to spend no more than a stated percentage of fair value of its investment portfolio over time. Accordingly, during fiscal year 2022, the Board of Trustees authorized the use of total return (income and appreciation) from its endowment resources at an aggregate rate of 5.7% (5.7% during fiscal year 2021) of the average fair value of its consolidated investment portfolio for the most recent five years. To the extent that the total return requirement for the current year is not fulfilled by interest and dividends, the University utilizes the appreciation of its endowment net assets for operating purposes. To the extent that the total return requirement for the current year is exceeded by interest and dividends, the University reinvests the excess in its net assets held for endowment.

**(k) Split-Interest Agreements and Perpetual Trusts**

The University's split-interest agreements with donors consist primarily of gift annuities, unitrusts, charitable remainder annuity trusts, and life income agreements. Assets held under these agreements are included in investments held for long-term purposes, and the carrying value of the assets is adjusted for changes in the fair value of the trust assets. For fiscal years 2022 and 2021, the fair values for split-interest agreements assets are \$154,694 and \$171,877, respectively. Contribution revenue is recognized at the dates the agreements are established. A liability for split-interest obligations is recorded when the agreement is established at the estimated net present value of future cash flows using a risk-adjusted discount rate commensurate with the duration of the estimated payments to the beneficiaries. The liabilities are adjusted during the term of the trusts for changes in the value of the assets, accretion of the discount and other changes in the estimates of future benefits. Interest rates in subsequent periods remain unchanged. For fiscal years 2022 and 2021, deferred gift liabilities of \$85,408 and \$83,670, respectively, are included in accounts payable and accrued expenses.



**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

The University is also the beneficiary of certain funds held in trust by others, which are administered by outside trustees. The present values of the estimated future cash receipts, which are measured by the fair value of the assets contributed to the trust, are recognized as assets and contribution revenues at the dates the trusts are established. The carrying value of the assets is adjusted for changes in the fair value of the trust assets. Inputs to the fair value estimate are classified in Level 3 of the fair value hierarchy.

**(l) Property, Plant, and Equipment**

Property, plant, and equipment are stated at cost or at estimated fair value if acquired by gift, less accumulated depreciation and amortization. Buildings used for research activities are componentized as site improvements, buildings, building services, and fixed equipment. Construction in progress costs are capitalized if the costs increase the square footage and/or useful life of the asset. The University capitalizes interest during periods of construction. Expenses incurred to restore property, plant, and equipment to like new condition or extend the useful life of the asset are capitalized. Minor renovations are expensed as incurred and are recorded within the University's consolidated statements of activities. The University reviews property, plant, and equipment for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable.

Depreciation of research building components is recorded using the straight-line method over the useful lives of the components ranging from 4 to 50 years. Depreciation of all other property, plant, and equipment is computed using the straight-line method over the lesser of the estimated useful lives of the assets or the lease term. Land is not subject to depreciation. Estimated useful lives for non-research property, plant, and equipment are as follows:

	<u>Years</u>
New building construction	40
Building and leasehold improvements	20
Land improvements	20
Equipment	4 to 15
Library books	10

The University reports gifts of property, plant, and equipment as net assets without donor restrictions unless explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as net assets with donor restrictions. Absent explicit donor stipulations about how long those long-lived assets must be maintained, the University reports expirations of donor restrictions when the donated or acquired long-lived assets are placed in service.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

**(m) Leases**

The University determines if an arrangement is or contains a lease at inception of the contract and classifies leases as either operating or finance depending upon the terms and conditions set forth in the contract. The University uses an incremental borrowing rate to determine the present value of lease payments when the implicit rate in the lease is not readily available. The current treasury rate and the University's current borrowing rate are factored into the incremental borrowing rate calculation.

The University recognizes operating lease expense within maintenance and facilities costs on the statements of activities on a straight-line basis over the lease term. On the consolidated balance sheets, right of use assets represent the University's right to use the underlying assets for the lease term and lease liabilities represent the University's obligation to make lease payments arising from the leases. Right of use assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Right of use assets are reduced each period by an amount equal to the difference between the operating lease expense and the amount of interest expense on the lease liability utilizing the effective interest method.

Finance lease assets are amortized on a straight-line basis within depreciation expense on the statements of activities over the lease term. Interest expense associated with finance leases is recorded using the effective interest method and is included in interest expense within the statements of activities. The University recognizes variable expenses, other than those related to rates or indices, in operating expenses in the period in which the obligation is incurred.

**(n) Museum Collections**

The University capitalizes museum collections. If purchased, collection items are capitalized at cost, and if donated, at their appraised or fair value on the accession date (the date on which the item is accepted by the Board of Trustees). There is no depreciation recorded on collection items.

**(o) Benefit Plans**

The University provides certain health care and life insurance benefits to retired employees and spouses under a defined benefit plan. Benefits include basic medical and major medical coverage. Certain categories of retirees receive dental coverage and group life insurance. Such post-retirement benefits are accounted for as deferred compensation over the estimated service lives of employees.

Post-employment benefits include benefits provided to former or inactive employees after employment but before retirement. For the University, such benefits include workers' compensation benefits, disability benefits, and benefits provided under various other programs.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

**(p) Derivative Instruments and Hedging Activities**

Derivative instruments related to the University's long-term debt are included in accounts payable and accrued expenses on the consolidated balance sheets. The change in the fair value of the derivative instruments is included in the net appreciation/depreciation in the statements of activities. The University selected the combination of variable rate bond issues and interest rate swap agreements to obtain fixed rate financing at the lowest available cost at the time of the transactions. The University is exposed to credit loss in the event of nonperformance by the counterparty to its long-term rate swaps. The interest rate swaps do not qualify for cash flow hedge accounting.

**(q) Refundable U.S. Government Grants for Student Loans**

Funds provided by the United States Government under the Federal Perkins, Nursing and Health Professions Student Loan programs were loaned to qualified students and were re-loaned after cash collections. These funds are ultimately refundable to the government and are recognized as a liability in the accompanying consolidated balance sheets. The Federal Perkins Loan Program ended June 30, 2018. Institutions receive guidance from the Department of Education on an annual basis with instructions for returning the federal portion of funding, based on the most recent Fiscal Operations Report and Application to Participate. Refer to Note 5 for further information.

**(r) Asset Retirement Obligations**

The University accounts for asset retirement obligations in accordance with asset retirement and environmental obligations guidance and is recorded as a liability on the balance sheets. This guidance primarily affects the way the University accounts for asbestos-related removal costs. The University accrues for asset retirement obligations in the period incurred if sufficient information is available to reasonably estimate the fair value of the obligation. Over time, the liability is accreted to its settlement value. Upon settlement of the liability, the University will recognize a gain or loss for any difference between the settlement amount and liability recorded.

**(s) Tuition and Fees**

Tuition and fees revenue is derived from degree programs as well as executive and continuing education programs. Tuition and fees are recognized as operating revenue in the period in which the University satisfies its performance obligations to provide education to students. Given the timing of each year's academic sessions, nearly all performance obligations on behalf of the University are completed within the fiscal year. The University recognizes tuition on a straight-line basis over each academic session based on published rates, net of explicit price concessions such as institutional aid. Institutional aid, in the form of grants and scholarships, includes amounts funded by endowment and gifts, and reduces the published price of tuition for students receiving such aid. Tuition and fees have been reduced by certain grants and scholarships in the amount of \$272,390 in 2022 and \$259,378 in 2021.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

The timing of billings, cash collections and revenue recognition results in accounts receivable and deferred revenue on the consolidated balance sheets. Receivables are recognized only to the extent that it is probable that the University will collect substantially all of the consideration to which it is entitled in exchange for goods and services transferred to the student. Receipts received in advance of goods and services performed are recorded as deferred revenue.

**(t) Grants and Contracts**

The University receives sponsored program grant and contract revenue from governmental and other sources generally for research activities and training programs. The funding may represent a nonreciprocal, nonexchange transaction in which the resources provided are for the benefit of the University, the funding organization's mission or the public at large or it may be a reciprocal transaction in exchange for an equivalent benefit in return.

Revenues from exchange transactions are recognized as performance obligations are satisfied, which in some cases, mirrors the timing of when related costs are incurred. Revenues from nonexchange transactions may be subject to conditions, in the form of both a barrier to entitlement and a refund of amounts paid (or a release from obligation to make future payments.) The University recognizes revenue earned from conditional nonexchange transactions and gifts when the barrier is satisfied, typically as related costs are incurred. At June 30, 2022, the University has grants or contracts for which it has not yet met all obligations to recognize revenue, or the right to recognize revenue is dependent on future events. These open commitments totaled \$362,230 and \$346,306 as of June 30, 2022 and 2021, respectively. It is expected that revenue will be recognized as the University fulfills its obligations over several years.

Grants and contracts awarded to the University are subject to audit by the various sponsoring agencies. Indirect costs recovered on grants and contracts are recorded at rates established by the University with the federal government, or predetermined by the nonfederal sponsor. Indirect cost rates for government grants and contracts are subject to audit, and subsequent final settlements are recorded as current period adjustments. Management believes the impact of any future settlements to be immaterial to the consolidated financial statements.

**(u) Gifts and Pledges and Contributions Receivable**

Gifts and pledges include revenues from unconditional nonexchange agreements with private sources and foundations. Unconditional gifts and pledges are recognized as revenue in the period received and reported as increases in the appropriate net asset category based on the presence or absence of donor-imposed restrictions. The University has elected the simultaneous release option for unconditional nonexchange transactions that are also subject to purpose restrictions. Under this option, net assets without donor restrictions will include the donor-restricted gifts and pledges whose purpose restrictions are met in the same reporting year as the revenue is recognized.

Nonexchange agreements are considered conditional if the terms of the agreement include both a right of return of assets received/promised and a barrier to entitlement. Conditional agreements are not recognized until the conditions and barriers on which they depend are met.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

Contributions receivable after one year are discounted to their present value using an interest rate for the year in which the promise was received and considers market and credit risk as applicable. Subsequent years' accretion of the discount is included in contribution revenue and used in accordance with any donor-imposed restrictions on the contributions. Allowance is made for uncollectible contributions receivable based upon management's judgment and analysis of the creditworthiness of the donors, past collection experience and other relevant factors.

**(v) Auxiliary Enterprises**

Auxiliary services exist to furnish goods or services to students, faculty, patients, staff, or incidentally to the general public. Auxiliary services revenue includes revenue from contracts with customers to provide student housing, food services, parking services and other miscellaneous activities and is recognized over the period during which the services are provided. Fees charged for auxiliary services are priced to offset the cost of the goods or services provided. The distinguishing characteristic of auxiliary services is that they are managed as a self-supporting activity. Revenues and expenses from auxiliary enterprises are reported as changes in net assets without donor restrictions.

A major component of auxiliary services revenue is revenue from contracts with students for housing and dining services. Operating revenue is recognized in the academic period in which the University satisfies its performance obligations to provide housing and dining services. Given the timing of each year's academic sessions, nearly all performance obligations on behalf of the University are completed within the fiscal year. The University recognizes housing and dining revenue on a straight-line basis over each academic session based on published rates.

**(w) Hospital and Faculty Practice Patient Care**

Hospital and faculty practice patient care revenue consists of net patient service revenues derived from contracts with patients in which the University's performance obligation is to provide various health care services as follows:

	<u>2022</u>	<u>2021</u>
Hospital services	\$ 2,989,781	\$ 2,838,773
Faculty practice patient care	510,824	510,598
Long-term care	55,322	49,086
Home health services	51,441	58,219
Ancillary and other services	<u>671,785</u>	<u>647,090</u>
<b>Total</b>	<u>\$ 4,279,153</u>	<u>\$ 4,103,766</u>

The University recognizes patient service revenue in the period in which performance obligations under contracts are met by providing healthcare services to patients. The University determines its performance obligations based on the nature of the services provided. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected charges. This method provides a reasonable depiction of the transfer of services over the

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients receiving inpatient acute care services or outpatient services. The performance obligation is measured from admission into the hospital, or the commencement of an outpatient service, to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge or completion of the outpatient services. The transaction price represents the amount of consideration expected from patients, third-party payors and others in exchange for providing the health care services rendered. Estimated net realizable amounts represent amounts due, net of explicit and implicit price concessions. Explicit price concessions include estimates of contractual adjustments that are determined based on contractual agreements, discount policies and historical experience. Implicit price concessions, primarily consisting of self-insured and copayment balances, are based on management's assessment of expected collections considering economic conditions, historical experience, trends in health care coverage and other collection indicators using a portfolio approach as a practical expedient to account for patients as a collective group rather than individually. After satisfaction of amounts due from insurance and reasonable efforts to collect from patients have been exhausted, the University follows established guidelines for placing certain past-due patient balances with collection agencies, subject to terms of certain restrictions on collection efforts as determined by the University. Accounts receivable from patients are written off after collection efforts have been followed in accordance with University policy. Certain revenue received from third-party payors is subject to audit and retroactive adjustment. Any changes in estimates under these contracts are recorded in current year operations.

Since all of its performance obligations relate to contracts with a duration of less than one year, the University has elected to apply the optional exemption provided in ASC 606-10-50-14a, and therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to previously are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

Strong Memorial Hospital, Highland Hospital, F.F. Thompson Health System, Inc., Noyes Memorial Hospital, The Memorial Hospital of William F. and Gertrude F. Jones, Inc., and St. James Hospital (collectively, the Hospitals) have agreements with third-party payors that provide for payments to the Hospitals at amounts different from its established rates. A summary of the payment arrangements with major third-party payors follows:

**Medicare**

Under the Medicare program, the Hospitals receive reimbursement under a prospective payment system (PPS) for inpatient services. Under the hospital inpatient PPS, fixed payment amounts per inpatient discharge are established based on the patient's assigned diagnosis related group (DRG). When the estimated cost of treatment for certain patients is higher than the average, providers typically will receive additional outlier payments. The Hospitals also receive reimbursement under a prospective payment system for certain medical outpatient services, based on service groups, called ambulatory payment classifications (APCs). Other outpatient services are based upon a fee schedule and/or actual costs. The Hospitals' Medicare cost reports are subject to audit by a fiscal

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

intermediary. The largest hospital within the consolidated entity has been audited and final settled through December 31, 2009.

**Medicaid and Other Third-Party Payors**

The New York Health Care Reform Act of 1996 (HCRA), as amended, governs payments to hospitals in New York State (NYS) through March 31, 2023. Under HCRA, Medicaid, workers' compensation, and no-fault payors payment rates are promulgated by the NYS Department of Health (DOH). Fixed payment amounts per inpatient discharge are established based on the patient's assigned case mix intensity similar to a Medicare DRG. Payments for outpatient payments are connected to Ambulatory Payment Groups (APGs) which use outpatient service intensity weights based on types of service and resource consumption. All other third-party payors, principally Blue Cross, other private insurance companies, Health Maintenance Organizations (HMOs), Preferred Provider Organizations (PPOs) and other managed care plans, negotiate payment rates directly with the hospitals. Such arrangements vary from DRG-based payment systems, to per diems, case rates and percentage of billed charges. If such rates are not negotiated, then the payors are billed at the Hospitals' established charges.

In addition, under HCRA, all non-Medicare payors are required to make surcharge payments for the subsidization of indigent care and other health care initiatives. The percentage amounts of the surcharge vary by payor and apply to a broader array of health care services. Also, certain payors are required to provide additional funds through surcharges on payments to hospitals for inpatient services or through voluntary election to pay a covered lives assessment directly to the DOH.

Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by material amounts in the near term. The Hospitals believe that they are in compliance, in all material respects, with all applicable laws and regulations and are not aware of any pending or threatened investigations involving allegations of potential wrongdoing. Compliance with such laws and regulations can be subject to future government review and interpretation. Noncompliance with such laws and regulations could result in repayments of amounts improperly reimbursed, substantial monetary fines, civil and criminal penalties and exclusion from the Medicare and Medicaid programs.

Revenue from Blue Cross and MVP Health Care accounted for approximately 25% and 3% and 26% and 3%, respectively, of the University's patient service revenue for the years ended June 30, 2022 and 2021. Revenue from Medicare and Medicaid programs (including Medicare Advantage and Medicaid Managed Care plans) accounted for approximately 30% and 14% and 31% and 13%, respectively, of the University's patient revenue for the years ended June 30, 2022 and 2021.

Both federal and NYS regulations provide for certain adjustments to current and prior years' payment rates and indigent care pool distributions based on industry-wide and hospital-specific data. The Hospitals have established estimates based on information presently available of the amounts due to or from Medicare, Medicaid, workers' compensation, and no-fault payors and amounts due from the indigent care pool for such adjustments. Those adjustments, which can be reasonably estimated, have been provided for in the accompanying financial statements. The Hospitals have estimated the potential impact of such adjustments based on the most recent

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

information available. However, those which are either (a) without current specific regulations to implement such adjustments, or (b) are dependent upon certain future events and cannot be reasonably estimated, have not been provided for in the accompanying financial statements. Management believes the amounts recorded in the accompanying financial statements will not be materially affected upon the implementation of such adjustments.

There are various other proposals at the federal and NYS levels relating to Medicare and Medicaid, that could, among other things, reduce reimbursement rates, modify reimbursement methods or increase managed care penetration. The ultimate outcome of these proposals and other market changes cannot presently be determined.

Health care revenue by major payor source is as follows:

	<u>2022</u>	<u>2021</u>
Medicare	\$ 1,294,777	\$ 1,258,250
Medicaid	579,212	542,943
Commercial third-party payors	1,512,030	1,479,479
Self-pay	55,107	52,351
Other	<u>838,027</u>	<u>770,743</u>
<b>Total</b>	<u>\$ 4,279,153</u>	<u>\$ 4,103,766</u>

**Charity Care**

The University provides care to patients who meet certain criteria under its charity care policy without charge or at amounts less than its established rates. Because the University does not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue. The University calculates the cost of charity care by applying the ratio of cost to gross charges to the gross uncompensated charges under the charity care policy. The University maintains records to identify and monitor the level of charity care it provides. The cost of services and supplies furnished under the University's charity care policy were approximately \$26,784 and \$36,815 in 2022 and 2021, respectively. The University received reimbursements of approximately \$18,277 and \$20,274 from New York State in 2022 and 2021, respectively, related to providing charity care to patients.



**UNIVERSITY OF ROCHESTER**  
**AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

**(x) New Authoritative Pronouncements**

ASU 2020-07 Not-for-Profit Entities (Topic 958) Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets

In September 2020, the FASB issued ASU 2020-07 – *Not-for-Profit Entities (Topic 958) Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*. This amendment requires the University to report contributed nonfinancial assets as a separate line item within the statements of activities and expanded reporting requirements for contributed nonfinancial assets, such as donor-imposed restrictions, fair value measurement, and qualitative information if the contributed nonfinancial assets were utilized or sold. The standard is effective for the fiscal year ending June 30, 2022. The adoption of ASU 2020-07 did not have a material impact on the University's financial statements for the fiscal years ended June 30, 2022 and 2021.

ASU 2018-14 Compensation – Retirement Benefits – Defined Benefit Plans – General (Subtopic 715-20) Disclosure Framework – Changes to the Disclosure Requirements for Defined Benefit Plans

In August 2018, the FASB issued ASU 2018-14 – *Compensation – Retirement Benefits – Defined Benefit Plans – General (Subtopic 715-20) Disclosure Framework – Changes to the Disclosure Requirements for Defined Benefit Plans*. The following disclosures were removed from defined benefit measurement: (1) amounts in accumulated other comprehensive income expected to be recognized as components of net periodic benefit cost over the next fiscal year; (2) amount and timing of plan assets expected to be returned to the employer; and (3) for public entities, the effects of a one-percentage-point change in assumed health care cost trend rates on the (a) aggregate of the service and interest cost components of net periodic benefit costs and (b) benefit obligation for postretirement health care benefits. In addition, the following disclosures are required: (1) the weighted-average interest crediting rates for cash balance plans and other plans with promised interest crediting rates and (2) an explanation of the reasons for significant gains and losses related to changes in the benefit obligation for the period. Refer to Note 10 for the additional disclosures for the University's post-retirement benefit plan.

**(y) Reclassification**

Certain other June 30, 2021 balances and amounts previously reported have been reclassified to conform to the June 30, 2022 presentation.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

**(2) Liquidity and Availability**

The University regularly monitors liquidity required to meet its operating needs and other contractual commitments, while also striving to maximize the investment of its available funds.

The following resources could be available within one year for general expenditures, such as operating expenses, scheduled principal payments on debt, and capital construction costs not financed with debt as of June 30:

	<b>2022</b>	<b>2021</b>
<b>Financial Assets:</b>		
Cash and cash equivalents	\$ 836,577	\$ 889,136
Short-term investments	868,278	892,621
Accounts receivable	481,730	485,239
Pledge payments available for operations	22,832	20,099
Other assets	1,305	690
Long-term investments appropriated for spending in the following year	131,830	121,055
<b>Financial assets available within one year</b>	2,342,552	2,408,840
<b>Liquidity Resources:</b>		
Bank lines and letters of credit (undrawn)	400,483	409,354
<b>Financial assets and liquidity resources available within one year</b>	\$ 2,743,035	\$ 2,818,194

The University's cash flows have seasonal variations during the year attributable to tuition billings, patient service billings, and concentration of contributions received at calendar and fiscal year ends. Based on historical experience, only the portion of contributions receivable for operations expected to be received within one year is considered liquid. The University invests cash in excess of daily requirements in short-term investments. Cash withdrawals from long-term investments generally coincide with the endowment spending distribution, but may be adjusted higher or lower based on the timing of gift receipts, capital calls, income and capital distributions, operating expenses and other factors affecting available cash. Endowment funds appropriated for spending are distributed to University department and program budgets for spending, subject to donor restrictions where applicable.

To help manage unanticipated liquidity needs, the University has committed bank lines and letters of credit in the amount of \$406,943 and \$412,854 with several banks as of June 30, 2022 and 2021, respectively, that can be drawn upon as needed during the year to manage cash flows. Amounts outstanding under lines of credit amounted to \$6,460 and \$3,500 as of June 30, 2022 and 2021, respectively.

In addition, the University has funds functioning as endowment (FFAE) of \$1,242,720 and \$1,474,070 as of June 30, 2022 and 2021, respectively. Although the University does not intend to

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

spend from FFAE funds other than amounts appropriated for expenditure as part of the annual budget approval process, these funds could be made available if necessary, subject to certain investment lock-up provisions as discussed in Note 6.

**(3) Accounts Receivable**

---

Accounts receivable, net at June 30 consist of the following:

	<u>2022</u>	<u>2021</u>
Patient accounts receivable	\$ 302,716	\$ 296,624
Governments, foundations and companies	93,198	95,316
Reinsurance recoveries	66,755	61,701
Retail pharmacy	41,744	46,195
Student receivables	6,737	9,170
Other	47,302	45,634
<b>Total accounts receivable, net</b>	<b>\$ 558,452</b>	<b>\$ 554,640</b>

The University grants credit without collateral to its patients, most of whom are insured under third-party payor agreements. The related receivables at June 30, 2022 and 2021 include approximately 49% from governmental payors, 41% from commercial third-party payors, and 10% from self-pay patients and other sources.

**(4) Contributions**

---

Contributions receivable, net, are summarized as follows at June 30:

	<u>2022</u>	<u>2021</u>
Unconditional promises expected to be collected in:		
Less than one year	\$ 36,008	\$ 28,708
One year to five years	17,895	29,253
More than five years	52,818	54,386
	<u>106,721</u>	<u>112,347</u>
Unamortized discount and allowance for uncollectibles	<u>(27,627)</u>	<u>(30,573)</u>
<b>Total contributions receivable, net</b>	<b>\$ 79,094</b>	<b>\$ 81,774</b>

Discount rates used to calculate the present value of contributions receivable ranged from 2% to 6% at June 30, 2022 and 2021. At June 30, 2022, the University had also received \$323,501 in bequest intentions and certain other conditional promises to give. These intentions and conditional promises to give are not recognized as assets. If they are received, they generally will be restricted for specific purposes stipulated by the donor, primarily endowments for faculty support, scholarships or general operating support of a particular department or division of the University.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

The University expended \$38,400 and \$37,151 for University relations and development for the years ended June 30, 2022 and 2021, respectively.

**(5) Notes Receivable**

Notes receivable, net, are summarized as follows at June 30:

	<b>2022</b>		
	<b>Gross Receivable</b>	<b>Allowance</b>	<b>Net Receivable</b>
Federal student loans	\$ 6,136	\$ 620	\$ 5,516
Institutional student loans	3,988	1,047	2,941
Other note receivable	5,442	-	5,442
<b>Total</b>	<b>\$ 15,566</b>	<b>\$ 1,667</b>	<b>\$ 13,899</b>
	<b>2021</b>		
	<b>Gross Receivable</b>	<b>Allowance</b>	<b>Net Receivable</b>
Federal student loans	\$ 7,861	\$ 944	\$ 6,917
Institutional student loans	3,988	970	3,018
Other note receivable	5,442	-	5,442
<b>Total</b>	<b>\$ 17,291</b>	<b>\$ 1,914</b>	<b>\$ 15,377</b>

Student loan programs are funded by donor contributions, other institutional sources and governmental programs, primarily the Federal Perkins Loan Program. The amounts received from the federal government's portion of the Perkins program are ultimately refundable to the federal government and are reported as a liability on the University's consolidated balance sheets as refundable U.S. Government grants for student loans. The Federal Perkins Loan Program ended June 30, 2018. Institutions are awaiting further guidance from the Department of Education with instructions for unwinding the Federal Perkins Loan program and returning the federal portion of funding. For fiscal years 2022 and 2021, the University refunded \$1,792 and \$2,233, respectively, to the U.S. Department of Education to reduce the Perkins Loan Program.

Student loans are often subject to unique restrictions and conditions; therefore, it is not practical to determine fair values. The allowance is intended to provide for loans, both in repayment status and not yet in repayment status (borrowers are still in school or in the grace period following graduation), that may not be collected.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
Notes to Consolidated Financial Statements  
June 30, 2022 and 2021  
(dollars in thousands)

**(6) Investments**

---

Investments were held for the following at June 30:

	<u>2022</u>	<u>2021</u>
Endowment and similar purposes	\$ 2,813,463	\$ 3,270,749
Property, plant, and equipment purposes:		
Debt service reserve held by trustees under debt agreements	29,847	44,379
Bond proceeds not yet expended	91,216	225,990
Other	1,190	1,219
Total property, plant, and equipment purposes	<u>122,253</u>	<u>271,588</u>
Other purposes	<u>282,851</u>	<u>280,455</u>
<b>Total investments held for long-term purposes</b>	<u>3,218,567</u>	<u>3,822,792</u>
<b>Short-term investments</b>	<u>868,278</u>	<u>892,621</u>
<b>Total investments</b>	<u>\$ 4,086,845</u>	<u>\$ 4,715,413</u>

For investment purposes, substantially all investments held for endowment and similar purposes participate in one of several pools, each with its own investment policy and objectives. The investment pool assets are owned by the separate endowment and similar funds within each pool based on the percent ownership of each fund to the pool. Income, realized and unrealized gains and losses are distributed based on the percent ownership of the pooled assets measured at fair value.

The University permits several of its investment managers to utilize forward contracts, currency options and futures with the specific authorization of the investment committee of the Board of Trustees. However, the University was not directly engaged in any of the above-mentioned derivative transactions as of June 30, 2022 and 2021. Management does not anticipate that losses, if any, resulting from its market or credit risks would materially affect the consolidated financial position of the University.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

The following tables present the fair value of investments recorded on the consolidated balance sheets as of June 30:

	Quoted Market Prices (Level 1)	Significant Observable Inputs (Level 2)	NAV as Practical Expedient (NAV)	2022 Total Fair Value
Short-term investments	\$ 288,076	\$ -	\$ -	\$ 288,076
Domestic bonds	383,586	208,495	-	592,081
Common equity:				
Domestic	108,966	33,462	199	142,627
Foreign	18,606	239,550	-	258,156
Equity:				
Absolute return	-	-	751,437	751,437
Global	70,525	-	-	70,525
Domestic	6,424	-	224,213	230,637
Foreign	769	-	330,363	331,132
Private	-	-	1,067,556	1,067,556
Real estate	539	-	71,347	71,886
Real assets	52,968	-	115,782	168,750
Other	103,581	10,401	-	113,982
<b>Total short and long term investments</b>	<b>\$ 1,034,040</b>	<b>\$ 491,908</b>	<b>\$ 2,560,897</b>	<b>\$ 4,086,845</b>

	Quoted Market Prices (Level 1)	Significant Observable Inputs (Level 2)	NAV as Practical Expedient (NAV)	2021 Total Fair Value
Short-term investments	\$ 334,285	\$ -	\$ -	\$ 334,285
Domestic bonds	254,934	212,200	-	467,134
Common equity:				
Domestic	108,545	60,652	199	169,396
Foreign	-	294,788	-	294,788
Equity:				
Absolute return	-	-	882,662	882,662
Global	81,981	-	-	81,981
Domestic	161,718	-	316,270	477,988
Foreign	846	-	332,501	333,347
Private	-	-	1,308,687	1,308,687
Real estate	-	-	86,697	86,697
Real assets	52,034	-	110,044	162,078
Other	106,218	10,152	-	116,370
<b>Total short and long term investments</b>	<b>\$ 1,100,561</b>	<b>\$ 577,792</b>	<b>\$ 3,037,060</b>	<b>\$ 4,715,413</b>

**(a) Fair Value Level 1**

Level 1 investments consist of cash and cash equivalents, equity, and fixed-income securities with observable market prices. Fair value for Level 1 is based upon quoted market prices in active markets.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

**(b) Fair Value Level 2**

Investments that are classified as Level 2 include domestic and foreign equities, as well as fixed-income securities that trade in markets that are not considered to be active. Fair value is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Inputs are obtained from various sources including market participants, dealers, and brokers.

**(c) Net Asset Value**

The net asset value (NAV) represents the University's ownership interest in certain alternative investments. The University has performed significant due diligence around these investments to ensure that NAV is an appropriate measure of fair value as of June 30.

The following tables provide information about alternative investments at NAV.

Strategy	2022 Fair Value	Unfunded Commitments	Redemption Frequency	Redemption Notice
Equity:				
Absolute return	\$ 751,437	\$ 41,821	Quarterly, Annually, 1, 3, & 5 Year Rolling Lock-ups	45 - 180 Days
Domestic	224,213	-	Monthly, Quarterly, 1 to 3 Year Rolling Lock-ups	45 - 180 Days
Foreign	330,363	-	Quarterly, Annually, 1, 3, & 5 Year Rolling Lock-ups	45 - 180 Days
Private	1,067,556	286,168	1 to 12 years	NA
Real estate	71,347	43,077	1 to 12 years	NA
Real assets	115,782	25,043	1 to 12 years	NA
Common equity (Domestic)	199	-	NA - held to maturity	NA
<b>Total alternative investments</b>	<b>\$ 2,560,897</b>	<b>\$ 396,109</b>		

Strategy	2021 Fair Value	Unfunded Commitments	Redemption Frequency	Redemption Notice
Equity:				
Absolute return	\$ 882,662	\$ 20,543	Quarterly, Annually, 1, 3, & 5 Year Rolling Lock-ups	45 - 180 Days
Domestic	316,270	10,000	Monthly, Quarterly, 1 to 3 Year Rolling Lock-ups	45 - 180 Days
Foreign	332,501	-	Quarterly, Annually, 1, 3, & 5 Year Rolling Lock-ups	45 - 180 Days
Private	1,308,687	162,082	1 to 12 years	NA
Real estate	86,697	32,478	1 to 12 years	NA
Real assets	110,044	27,384	1 to 12 years	NA
Common equity (Domestic)	199	-	NA - held to maturity	NA
<b>Total alternative investments</b>	<b>\$ 3,037,060</b>	<b>\$ 252,487</b>		

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
Notes to Consolidated Financial Statements  
June 30, 2022 and 2021  
(dollars in thousands)

**(7) Property, Plant, and Equipment**

As of June 30, 2022 and 2021, the University's investment in property, plant, and equipment is as follows:

	<u>2022</u>	<u>2021</u>
Buildings and improvements	\$ 3,530,734	\$ 3,396,629
Land improvements	78,939	78,593
Leasehold improvements	157,508	131,592
Equipment owned	1,713,640	1,696,198
Library books	250,142	238,323
Subtotal	<u>5,730,963</u>	<u>5,541,335</u>
Less accumulated depreciation	<u>(3,647,937)</u>	<u>(3,450,481)</u>
Subtotal	2,083,026	2,090,854
Land	20,635	20,472
Museum collections	43,048	40,910
Construction in progress	<u>292,888</u>	<u>155,886</u>
<b>Total property, plant and equipment, net</b>	<u><u>\$ 2,439,597</u></u>	<u><u>\$ 2,308,122</u></u>



**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

**(8) Long-Term Debt**

The following is a summary of the University's long-term indebtedness as of June 30, including unamortized premiums of \$117,045 and \$126,622 and bond issuance costs of \$10,375 and \$10,336, for the years ended June 30, 2022 and 2021, respectively:

	<u>Fiscal year maturity</u>	<u>Interest rate</u>	<u>2022</u>	<u>2021</u>
<b>University of Rochester:</b>				
Fixed Rate:				
MCIDC Series 2011; 2013; 2015; 2017; 2020	2024 - 2050	0.47% - 5.31%	1,212,447	1,269,273
Private Placement Notes	2047 - 2052	3.26% - 4.31%	196,080	88,929
Other Notes	2026	3.26%	2,411	3,214
Obligations under finance leases	2023 - 2031	0.85% - 4.21%	20,153	22,573
Total University			1,431,091	1,383,989
<b>Highland Hospital of Rochester:</b>				
Fixed Rate:				
MCIDC Series 2015; 2020	2045 - 2050	3.00% - 5.00%	66,153	68,019
Variable rate:				
DASNY Series 1994B	2023	5.50%	1,933	2,805
Total Highland Hospital			68,086	70,824
<b>F. F. Thompson Health System, Inc.:</b>				
Fixed Rate:				
OCLDC Series 2017	2040	2.79% - 3.30%	30,683	32,305
Other Notes	2025 - 2030	3.55% - 7.71%	5,200	5,729
Obligations under finance leases	2023 - 2026	0.00% - 8.50%	3,163	3,968
Variable rate:				
DASNY Series 2012	2039	3.00%	11,015	11,470
Total F. F. Thompson Health System, Inc.			50,061	53,472
<b>Livingston Health Care System, Inc.:</b>				
Fixed Rate:				
LCIDA Series 2005	2030	5.00% - 6.00%	3,792	4,100
Obligations under finance leases	2023 - 2027	3.21% - 5.00%	269	708
Total Livingston Health Care System, Inc.			4,061	4,808
<b>Memorial Hospital of William F. and Gertrude F. Jones, Inc.:</b>				
Fixed Rate:				
Obligations under finance leases	2023	5.60%	46	324
Total Memorial Hospital of William F. and Gertrude F. Jones, Inc.			46	324
<b>St. James Hospital:</b>				
Fixed Rate:				
New Market Tax Credit Loans	2041	1.05%	7,299	7,680
Other Notes	2028	0.00% - 3.85%	4,917	5,595
Total St. James Hospital			12,216	13,275
<b>Total Long-term debt</b>			<b>\$ 1,565,561</b>	<b>\$ 1,526,692</b>

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

**(a) Fiscal year 2022 Transactions**

During fiscal year 2022, the University issued \$111,000 in private placement notes, maturing July 2052. The private placement notes were issued to finance the following (1) construction and renovation of certain hospital and educational facilities; (2) construction of an addition to the existing Laboratory for Laser Energetics building; and (3) construction of a new clinical building in Geneseo, New York.

**(b) Interest Rate Swaps**

F. F. Thompson Health System, Inc. executed interest rate swaps with third-parties. These swaps have a combined notional amount of \$11,015 and the contractual relationship under this agreement will last until November 1, 2025.

Interest rate swaps are valued using both observable and unobservable inputs, such as quotations received from the counterparty, dealers or brokers, whenever available and considered reliable. In instances where models are used, the value of the interest rate swap depends upon the contractual terms of, and specific risks inherent in, the instrument as well as the availability and reliability of observable inputs. Such inputs include market prices for reference securities, yield curves, credit curves, measures of volatility, prepayment rates, assumptions for nonperformance risk, and correlations of such inputs. The University's interest rate swap arrangements have inputs which can generally be corroborated by market data and are therefore classified within Level 2.

Appreciation (depreciation) of interest rate swaps was \$542 and \$(387) for the years ended June 30, 2022 and 2021, respectively, and are included in nonoperating net (depreciation) appreciation on the consolidated statements of activities. Activity related to interest rate swaps affect net assets without donor restrictions and, in the consolidated statements of cash flows, are included in changes in accounts payable and accrued expenses in the operating activities section.

**(c) Collateral**

Highland Hospital of Rochester has a letter of credit in place for DASNY Series 1994B, which expires July 2023. F. F. Thompson Health System, Inc. has a letter of credit in place for DASNY Series 2012, which expires in April 2026.

**(d) Finance Leases**

During fiscal year 2022, the University issued \$3,696 in finance lease obligations for various equipment. The leases are being repaid at various rates with maturity dates through September 2030.

The University leases equipment for educational, research, and patient care purposes under finance leases.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

Lease cost recognized in the consolidated statements of activities is summarized as follows:

	<b>2022</b>	<b>2021</b>
<b>Finance lease cost:</b>		
Amortization of right-of-use assets	\$ 8,305	\$ 7,265
Interest on lease liabilities	1,523	1,017
Total lease cost	\$ 9,828	\$ 8,282
	<b>2022</b>	<b>2021</b>
<b>Finance leases reported under:</b>		
Property, plant, and equipment, net	\$ 20,945	\$ 25,460
Long-term debt	\$ 23,631	\$ 27,573
Weighted average remaining lease term - finance leases	3.61 years	4.81 years
Weighted average discount rate - finance leases	3.7%	4.1%

**(e) Required Principal Payments**

Required composite principal payments for long-term debt, net of unamortized discount or premium and bond issuance costs, for each of the years in the five-year period ending June 30, 2027 and thereafter are as follows:

	<b>Principal Portions of Lease Payments</b>	<b>Principal Portions of Debt</b>	<b>Total</b>
2023	\$ 6,855	\$ 67,596	\$ 74,451
2024	5,266	75,797	81,063
2025	4,911	75,353	80,264
2026	3,655	71,244	74,899
2027	2,172	74,353	76,525
Thereafter	772	1,177,587	1,178,359
<b>Total</b>	<b>\$ 23,631</b>	<b>\$ 1,541,930</b>	<b>\$ 1,565,561</b>

The University incurred \$43,670 and \$46,094 of interest expense for the years ended June 30, 2022 and 2021, respectively, net of interest capitalization of \$8,407 and \$7,174 for the years ended June 30, 2022 and 2021, respectively.

**(9) Operating Leases**

The University leases laboratories, office space, medical offices, and equipment for educational, research, and patient care purposes under operating leases expiring through 2040. The real estate lease agreements typically have initial terms of five to twenty years and may include one or more options to renew, which can extend the lease term five to ten years. The exercise of lease renewal

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

options is at the University's sole discretion. When determining the lease term, the University includes options to extend or terminate the lease when the option to exercise is certain.

The components of lease expense included in maintenance and facilities costs in the consolidated statements of activities for the year ended June 30 were as follows:

	<u>2022</u>	<u>2021</u>
Operating lease cost	\$ 51,132	\$ 50,193
Variable lease cost	506	951
<b>Total</b>	<u>\$ 51,638</u>	<u>\$ 51,144</u>
<b>Weighted Average Remaining</b>		
Operating leases	7.33 years	5.85 years
<b>Weighted Average Discount Rate</b>		
Operating leases	4.3 %	3.8 %

Maturities of operating lease liabilities were as follows:

Year ending June 30,	<u>University</u>	<u>Related Entities</u>	<u>Total</u>
2023	\$ 41,197	\$ 5,020	\$ 46,217
2024	35,720	4,341	40,061
2025	27,654	3,544	31,198
2026	19,839	2,805	22,644
2027	13,504	2,343	15,847
Thereafter	\$ 38,308	\$ 11,512	49,820
<b>Total lease payments</b>	<u>176,222</u>	<u>29,565</u>	<u>205,787</u>
<b>Less imputed interest</b>	<u>(13,944)</u>	<u>(7,523)</u>	<u>(21,467)</u>
<b>Total</b>	<u>\$ 162,278</u>	<u>\$ 22,042</u>	<u>\$ 184,320</u>

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

**(10) Benefit Plans**

---

**(a) Self-insurance Plans – University**

The University is self-insured for workers' compensation. Liabilities for asserted and unasserted claims under the workers' compensation program at June 30, 2022 were discounted by 2.98% and amounted to \$57,754 (1.45% and \$65,288 in 2021) based on estimates provided by actuaries. These liabilities are offset by receivables for the expected insurance direct payments against these claims of \$17,014 at June 30, 2022 (\$18,320 at June 30, 2021). The liabilities are included in accrued pension, post-retirement, and post-employment liabilities, and the receivables are included in other assets on the consolidated balance sheets. The University has a surety bond with Liberty Mutual Insurance Company to cover potential liabilities under the University's self-insured workers' compensation program.

The University is self-insured for health care benefits. Based on estimates provided by actuaries, the University's obligation for incurred but not reported claims was \$16,311 and \$19,115 as of June 30, 2022 and 2021, respectively. These amounts are included in accounts payable and accrued expenses on the consolidated balance sheets and have not been discounted.

**(b) Self-insurance Plans – Highland Hospital and its Subsidiaries**

Highland Hospital and its subsidiaries are self-insured for workers' compensation claim losses and expenses. Effective May 7, 2021, the entity and its subsidiaries entered into a surety bond arrangement in the amount of \$8,884 and is maintained as security for workers' compensation claims. The previous letter of credit arrangement terminated as of June 30, 2021. Based on estimates provided by actuaries, liabilities for asserted and unasserted claims under the workers' compensation program at June 30, 2022 were discounted by 3.00% and amounted to \$7,241 (1.25% and \$7,947 in 2021). These liabilities are offset by receivables for the expected insurance direct payments against these claims of \$1,465 at June 30, 2022 (\$1,932 at June 30, 2021). The liabilities are included in accrued pension, post-retirement, and post-employment liabilities, and the receivables are included in other assets on the consolidated balance sheets.

**(c) Post-employment Benefits – University**

The University's accrued post-employment benefits, inclusive mostly of workers' compensation and disability benefits, amounted to \$105,466 and \$123,389 at June 30, 2022 and 2021, respectively, and are recorded in accrued pension, post-retirement and post-employment on the consolidated balance sheets.

**(d) Post-retirement Benefit Plan – University**

The University's post-retirement benefit plan includes basic medical, major medical, dental coverage, and life insurance. Benefit levels differ for current retirees, current employees eligible to retire, and current employees not eligible to retire. The University incurred post-retirement plan expense of \$9,827 and \$12,776 for the years ended June 30, 2022 and 2021, respectively. The service cost component of post-retirement plan expense is recorded in fringe benefits expense on the consolidated statements of activities. The remaining nonservice cost items are recorded in other

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

changes, net as nonoperating activities. The benefit obligation for this plan for the years ended June 30, 2022 and 2021 includes the following components:

	<u>2022</u>	<u>2021</u>
<b>Change in benefit obligation:</b>		
Benefit obligation at beginning of year	\$ 224,327	\$ 260,938
Service cost	5,252	5,661
Interest cost	5,408	6,045
Plan participants' contributions	2,263	5,904
Amendments/curtailments/special termination	(1,106)	(27,158)
Actuarial gain	(62,672)	(14,575)
Benefits paid	(8,611)	(12,929)
Medicare Part D prescription drug federal subsidy	400	441
<b>Benefit obligation at end of year</b>	<u>\$ 165,261</u>	<u>\$ 224,327</u>
<b>Change in plan assets:</b>		
Fair value of plan assets at beginning of year	\$ -	\$ -
Employer contributions	5,948	6,584
Plan participants' contributions	2,263	5,904
Medicare Part D prescription drug federal subsidy	400	441
Benefits paid	(8,611)	(12,929)
<b>Fair value of plan assets at end of year</b>	<u>\$ -</u>	<u>\$ -</u>
<b>Components of accrued benefit:</b>		
Funded status	\$ (165,261)	\$ (224,327)
Net actuarial (gain)/ loss	(1,541)	62,429
Prior service cost	(23,884)	(24,909)
<b>Accrued benefits</b>	<u>\$ (190,686)</u>	<u>\$ (186,807)</u>
<b>Amounts recognized in the consolidated balance sheets consist of:</b>		
Accrued post-retirement benefit cost	\$ (186,807)	\$ (180,615)
Net periodic benefit cost	(9,827)	(12,776)
Employer contributions	5,948	6,584
Accrued benefits	(190,686)	(186,807)
Amount recorded in unrestricted net assets	25,425	(37,520)
<b>Net amount recognized in the consolidated balance sheets</b>	<u>\$ (165,261)</u>	<u>\$ (224,327)</u>
<b>Components of net periodic benefit cost:</b>		
Service cost	\$ 5,252	\$ 5,661
Interest cost	5,408	6,045
Amortization of prior service cost	(2,131)	(2,051)
Amortization of net actuarial loss	1,298	3,121
<b>Net periodic benefit cost</b>	<u>\$ 9,827</u>	<u>\$ 12,776</u>
<b>Amounts recorded in unrestricted net assets:</b>		
Prior service credit	\$ (1,106)	\$ (27,158)
Net gain during period	(62,672)	(14,575)
Amortization recognition	(1,298)	(3,121)
Prior service cost	2,131	2,051
<b>Total amount recognized in other non-operating expense</b>	<u>\$ (62,945)</u>	<u>\$ (42,803)</u>

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

Estimated future contributions and benefit payments are as follows:

	<b>Estimated Contributions / Benefit Payments</b>
2023	\$ 10,390
2024	10,623
2025	10,814
2026	11,043
2027	11,141
2028 to 2029	56,936

Benefits are valued based upon the projected unit cost method. The weighted average assumptions used at the measurement date, June 30, are as follows:

	<b>2022</b>	<b>2021</b>
Discount rate for obligation	4.50%	2.75%
Health care cost trend rate -		
Initial pre age 65	6.75%	6.75%
Initial post age 65	N/A	N/A
Initial post age 65 (Medicare Advantage)	N/A	N/A
Initial prescription drug	6.75%	6.75%
Health care cost trend rate - Final	3.78%	3.78%
Year final trend rate is reached	2075	2075

The Medicare Prescription Drug Improvement and Modernization Act of 2003 provides for a direct government subsidy for employers who continue to offer a retiree drug program that is deemed to be actuarially equivalent in the government plan. Due to a Plan amendment effective January 1, 2021, the University no longer sponsors coverage for most Medicare-eligible retirees. Instead, those retirees are offered coverage through a benefits exchange. As such, the University is no longer eligible to apply for the Medicare Part D prescription drug federal subsidy for those retirees. The University does, however, offer a retiree drug program to Medicare-eligible retirees who are on long-term disability. The receipts for those retirees would be considered under post-employment, not post-retirement benefits.

Employers are required to recognize the over-funded or under-funded status of defined benefit pension and post-retirement plans as assets or liabilities in its consolidated balance sheets and to recognize changes in that funded status in the year in which the changes occur through changes in net assets without donor restrictions. In addition, employers are required to measure the funded status of the plan as of the consolidated balance sheet date.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

Significant (gains)/losses occurring during the period ending June 30, 2022 were as follows:

As of July 1, 2021, the census data was refreshed to reflect changes in the population between the prior and current valuation dates. Furthermore, fewer than expected post-65 retirees elected subsidized benefits through the Via Exchange. Demographic changes different from assumed resulted in a decrease in liabilities.

As of July 1, 2021, the baseline gross claims used to project future pre-65 retiree healthcare costs were updated to reflect the updated actuarial models for the current valuation date. Less than expected increases in baseline claim costs resulted in a decrease in liabilities.

As of July 1, 2021, premiums for future pre-65 retirees increased less than expected. Less than expected increase in premiums resulted in an increase in liabilities.

As of July 1, 2021, cross accumulation of pre-65 retiree plan deductibles and out-of-pocket maximums is no longer allowed for out-of-network services. This change was valued as a plan amendment and resulted in a decrease of liabilities.

As of June 30, 2022, the discount rate was updated from 2.75% to 4.5%. The change in discount rate resulted in a decrease in liabilities.

As of June 30, 2022, the mortality improvement scale assumption was revised to Scale MP-2020 to Scale MP-2021 on a generational basis. The revised assumption resulted in an increase in liabilities.

As of June 30, 2022, the annual rate of increase in healthcare costs was revised to better reflect future expectations, including updating long-term rates based on the SOA Long Term Healthcare Cost Trends Model v2022\_f4 (the Getzen model). A review of published national trend survey data in relation to the retiree health plan offerings was the basis for this change. The revised assumption resulted in an increase in liabilities.

**(e) Retirement Plan – University**

The University provides a 403(b) defined contribution retirement plan to its employees. The University of Rochester's Retirement Program is administered and record kept by TIAA. Under this plan, the University made contributions of \$129,873 and \$97,966 in 2022 and 2021, respectively, which were vested for the benefit of the participants.

**(f) Retirement Plans – Highland Hospital and Subsidiaries**

The defined benefit retirement plan of Highland Hospital covers employees of Highland Hospital, The Highlands Living Center and Highland Community Development Corporation who have completed two years of continuous employment. The benefits for this plan are based primarily on years of service and employees' pay near retirement. The funding policy is to contribute, annually, an amount consistent with the requirement of the Employee Retirement Income Security Act. Effective August 3, 2010, participation in the plan was frozen.



**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

Retirement plan expense of \$11,890 and \$12,371 was incurred for fiscal years ended June 30, 2022 and 2021, respectively. In addition, a pension related benefit other than net periodic pension cost of \$26,544 and \$38,394 for the fiscal years ended June 30, 2022 and 2021, respectively, was recorded in other changes on the consolidated statements of activities.

The following tables present the changes in the plan benefit obligation and the fair value of the plan assets for the years ended June 30, 2022 and 2021 and the funded status of the plan at June 30, 2022 and 2021.

	<b>2022</b>	<b>2021</b>
<b>Change in benefit obligation:</b>		
Benefit obligation at beginning of year	\$ 259,251	\$ 256,184
Service cost	5,555	5,868
Interest cost	5,638	5,807
Actuarial (gain) loss	(44,859)	1,873
Plan settlements	(35,982)	-
Benefits and expenses paid	(10,370)	(10,481)
<b>Benefit obligation at end of year</b>	<b>\$ 179,233</b>	<b>\$ 259,251</b>
<b>Accumulated benefit obligation</b>	<b>\$ 170,977</b>	<b>\$ 248,447</b>
	<b>2022</b>	<b>2021</b>
<b>Change in plan assets:</b>		
Fair value of plan assets at beginning of year	\$ 182,223	\$ 134,900
Actual return on plan assets	(19,012)	39,570
Employer contribution	6,261	18,234
Plan settlements	(35,981)	-
Benefits and expenses paid	(10,370)	(10,481)
<b>Fair value of plan assets at end of year</b>	<b>\$ 123,121</b>	<b>\$ 182,223</b>
<b>Amounts recognized in the balance sheets consists of:</b>		
Accrued benefit cost (accrued pension, post-retirement, and post-employment )	\$ (21,580)	\$ (15,951)
Amount recognized in unrestricted net assets (other non-operating expense)	(34,532)	(61,076)
<b>Funded status</b>	<b>\$ (56,112)</b>	<b>\$ (77,027)</b>
<b>Components of net periodic benefit cost:</b>		
Service cost	\$ 5,555	\$ 5,868
Interest cost	5,638	5,807
Expected return on plan assets	(11,308)	(9,284)
Settlement loss recognized	7,757	-
Amortization of unrecognized loss	4,248	9,980
<b>Net periodic benefit cost</b>	<b>\$ 11,890</b>	<b>\$ 12,371</b>

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

Benefits are valued based upon the projected unit credit cost method. The assumptions used for the plan at the measurement date are as follows:

	<u>2022</u>	<u>2021</u>
Discount rate for obligation	4.76%	2.77%
Effective discount rate for service cost	2.91%	3.00%
Effective rate of interest on service cost	2.68%	2.73%
Future compensation increase rate	3.00%	3.00%
Long-term rate of return on plan assets	6.75%	6.75%

Discount rates used to determine the benefit obligations are based on the yields on high-grade corporate bonds with maturities similar to the projected benefit payments.

To develop the expected long-term rate on assets assumption, the plan sponsor considered the current level of expected returns on risk free investments, the historical level of the risk premium associated with the other asset classes in which the portfolio is invested and the expectations for future returns of each asset class. The expected return for each asset class was then weighted based on the target asset allocation to develop the expected long-term rate of return on assets assumption.

The Plan assets are managed by an investment manager. The investment manager monitors financial markets and adjusts strategy accordingly. The Plan's overall portfolio mix of fixed income and equity securities was based upon asset allocation modeling taking into consideration historical return patterns and risk factors. The Plan believes that the current mix of plan assets provides an appropriate level of return to achieve current assumed plan return assumptions. For the year ended June 30, 2022, the Plan had target asset allocation ranges of 50% - 75% public equity, 10% - 50% public debt, 0% - 20% private debt and 0% -25% alternatives.

The asset allocation ranges established by this investment policy represent a long-term perspective, and as such, rapid unanticipated market shifts or changes in economic conditions may cause the asset mix to fall outside of the policy range. These divergences should be of a short-term nature.

Risk mitigation is achieved by diversifying investments across multiple asset classes, by investment in high quality securities and by permitting flexibility in the balance of investments in the permitted asset classes. Market risk inheres in any portfolio but the investment policies and strategies are designed to avoid concentration of risk in one entity, industry, country, or commodity.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

The following assets were recorded at fair value within the pension assets of the Hospital as of June 30:

Description	<b>2022</b>		<b>Total Fair Value</b>
	<b>Level 1</b>	<b>NAV</b>	
Cash and cash equivalents	\$ 1,249	\$ -	\$ 1,249
Mutual and exchange traded funds	13,365	-	13,365
Collective investment trusts	-	92,902	92,902
Other pooled investment funds	-	7,851	7,851
Limited partnerships	-	7,754	7,754
<b>Total</b>	<b>\$ 14,614</b>	<b>\$ 108,507</b>	<b>\$ 123,121</b>

Description	<b>2021</b>		<b>Total Fair Value</b>
	<b>Level 1</b>	<b>NAV</b>	
Cash and cash equivalents	\$ 6,750	\$ -	\$ 6,750
Mutual and exchange traded funds	10,517	-	10,517
Collective investment trusts	-	119,398	119,398
Other pooled investment funds	-	26,247	26,247
Limited partnerships	-	19,311	19,311
<b>Total</b>	<b>\$ 17,267</b>	<b>\$ 164,956</b>	<b>\$ 182,223</b>

Fair value for Level 1 is based upon quoted market prices. As a practical expedient, Highland Hospital uses its ownership interest in the NAV to determine the fair value of the investments.

Highland Hospital expects to contribute \$5,637 to the Plan in fiscal year 2023.

Scheduled estimated future benefit payments for fiscal years ending June 30 are as follows:

	<b>Pension Benefits</b>
2023	\$ 8,700
2024	9,223
2025	9,798
2026	10,340
2027	10,851
2028 to 2032	60,033
<b>Total estimated future payments</b>	<b>\$ 108,945</b>

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

In addition, Highland Hospital has a 403(b) defined contribution plan and the cost was \$4,884 and \$4,500 for fiscal years ending June 30, 2022 and 2021, respectively, and is recorded in benefits expense on the consolidated statements of activities.

**(g) Retirement Plan – F.F. Thompson Health System, Inc.**

F.F. Thompson Health System, Inc. sponsors a noncontributory defined benefit pension plan, the Thompson Health Pension Plan (the FFT Plan), covering all eligible employees. Benefits under the FFT Plan are based on each participant's years of service and compensation, as defined by the FFT Plan document. As of January 1, 2018, the accrued benefits and participation of employees were frozen. As of that date, no new participants are eligible to participate in the FFT Plan after December 31, 2017, and benefit accruals for participants under the FFT Plan ceased. The funded status of the FFT Plan as of December 31, 2021 and 2020 was \$(9,536) and \$(16,409), respectively.

**(h) Retirement Plan – UR Medicine Home Care and Subsidiaries**

UR Medicine Home Care has a noncontributory defined benefit cash balance pension plan covering many of its employees, past and present. This plan was frozen in December 2002. There will be no new participants and no new annual contributions for existing participants. Accounts for existing participants will continue to be credited annually for interest earned. UR Medicine Home Care will have an ongoing requirement for funding of the plan.

The annual measurement date for the Plan is December 31. The funded status of this plan as of December 31, 2021 and 2020 was \$(1,370) and \$(2,887), respectively.

**(i) Retirement Plan – The Memorial Hospital of William F. and Gertrude F. Jones, Inc.**

The Hospital sponsors a noncontributory defined benefit pension plan (plan) covering all eligible employees. The plan was amended to state that Hospital employees hired after December 31, 2006 were no longer eligible to participate in the plan. Additionally, the plan was amended to freeze benefit accruals effective March 31, 2011 for all participants. The annual measurement date for the Plan is June 30. The funded status of this plan as of June 30, 2022 and 2021 was \$(3,102) and \$(4,879), respectively.

**(j) Retirement Plan – Livingston Health Care System, Inc. D/B/A Noyes Health**

The System has a noncontributory defined benefit pension plan that covers all eligible employees as of November 30, 2002. Effective November 2002, the Plan was amended to freeze participation and benefit accruals. Effective June 30, 2020, Noyes Health amended their year-end from December 31 to June 30. As such, the annual measurement date for the Plan is June 30. The funded status of this plan as of June 30, 2022 and 2021 was \$(1,165) and \$(1,740), respectively.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

**(11) Investment in Captive Insurance Company**

---

The University, together with other universities and teaching hospitals, has formed a captive insurance company (captive) to insure the professional liability risks of the shareholders. The dissolution provisions of the captive agreement indicate that the University's financial participation (based on the percentage of premiums paid) is approximately 7% of the financial results of the captive. Due to the University's significant influence in the captive, the investment in the captive has been recorded under the equity method. For fiscal years 2022 and 2021, the University has recorded \$29,364 and \$29,426, respectively, in investments held for long-term purposes.

The University's premiums are based on its professional liability experience and a shared risk factor with the other participants. Premiums are subject to retrospective adjustment based on, among other things, actual loss experience of the University.

**(12) Professional Liability Claims**

---

The University's coverage for professional liability insurance is provided under insurance policies obtained jointly with other universities and teaching hospitals. The primary layer of coverage, as well as the buffer and self-insured layers of excess insurance, were written by MCIC Vermont, Inc. (a Risk Retention Group) formed and directed by the participating insured institutions. Multiple layers of excess insurance were purchased from several different insurance companies. The maximum coverage for the University is \$225,000 per claim. The per claim coverage amount at each of the five participating institutions has been tailored to their own experience and exposures.

The insurance claims receivable, as calculated by the actuaries, was approximately \$66,755 and \$61,701 as of June 30, 2022 and 2021, respectively, and has been included in accounts receivable as shown in Note 3. A corresponding increase to the accrued professional liability cost has been included in accounts payable and accrued expenses.

Based on estimates provided by the actuaries retained by MCIC Vermont, Inc., the University's obligations for incurred but not reported claims were \$41,079 and \$38,270 as of June 30, 2022 and 2021, respectively. These amounts have not been discounted and are included in accounts payable and accrued expenses on the consolidated balance sheets.

**(13) Commitments and Contingencies**

---

In the ordinary course of operations, the University is named as a defendant in various lawsuits, or events that occur which could lead to litigation, claims, or assessments. Although the outcome of such matters cannot be predicted with certainty, management believes that insurance coverage is sufficient to cover current or potential claims, or that the final outcomes of such matters will not have a material adverse effect on the consolidated financial position.

At June 30, 2022, the University has entered into construction contracts and commitments aggregating \$2,298,799 (\$1,222,763 at June 30, 2021) of which \$1,404,485 (\$822,654 at June 30, 2021) had been fulfilled.

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

**(14) Expenses by Functional and Natural Classification**

Expenses are presented by functional classification in accordance with the overall service missions of the University. Each functional classification displays all expenses related to the underlying operations by natural classification. Depreciation, maintenance, and facilities costs are allocated to functional categories based on square footage occupancy. Interest expense on external debt is allocated to the functional categories which benefited from the proceeds of the external debt.

Other components of net periodic benefit pension costs are a component of other changes, net on the statement of activities and is allocated based on the salaries that benefit the functional area.

Functional expenses for the years ended June 30 consisted of the following:

	<b>2022</b>				
	<b>Academic instruction</b>	<b>Research</b>	<b>Hospital and Patient Care</b>	<b>Admin and Other</b>	<b>Total</b>
Compensation	\$ 486,960	\$ 212,724	\$ 2,417,279	\$ 171,322	\$ 3,288,285
Supplies	26,316	26,461	984,903	3,436	1,041,116
Utilities and maintenance	50,347	56,312	116,780	30,795	254,234
Depreciation expense	86,800	24,989	155,331	1,124	268,244
Interest expense	14,159	8,932	16,324	4,255	43,670
Services and other	35,630	31,127	398,754	71,505	537,016
Total operating expenses	<u>\$ 700,212</u>	<u>\$ 360,545</u>	<u>\$ 4,089,371</u>	<u>\$ 282,437</u>	<u>\$ 5,432,565</u>
Other components of net periodic benefit pension costs	\$ 871	\$ 342	\$ 1,923	\$ 324	\$ 3,460
Total non-operating activities	<u>871</u>	<u>342</u>	<u>1,923</u>	<u>324</u>	<u>3,460</u>
Total functional expenses	<u>\$ 701,083</u>	<u>\$ 360,887</u>	<u>\$ 4,091,294</u>	<u>\$ 282,761</u>	<u>\$ 5,436,025</u>

  

	<b>2021</b>				
	<b>Academic instruction</b>	<b>Research</b>	<b>Hospital and Patient Care</b>	<b>Admin and Other</b>	<b>Total</b>
Compensation	\$ 456,412	\$ 197,438	\$ 2,193,146	\$ 188,973	\$ 3,035,969
Supplies	17,013	25,454	922,571	2,138	967,176
Utilities and maintenance	45,728	54,912	115,048	21,727	237,415
Depreciation expense	84,446	23,838	156,536	725	265,545
Interest expense	14,758	9,594	17,216	4,526	46,094
Services and other	6,115	18,347	315,031	45,379	384,872
Total operating expenses	<u>\$ 624,472</u>	<u>\$ 329,583</u>	<u>\$ 3,719,548</u>	<u>\$ 263,468</u>	<u>\$ 4,937,071</u>
Other components of net periodic benefit pension costs	\$ 1,363	\$ 543	\$ 10,845	\$ 523	\$ 13,274
Total non-operating activities	<u>1,363</u>	<u>543</u>	<u>10,845</u>	<u>523</u>	<u>13,274</u>
Total functional expenses	<u>\$ 625,835</u>	<u>\$ 330,126</u>	<u>\$ 3,730,393</u>	<u>\$ 263,991</u>	<u>\$ 4,950,345</u>

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
Notes to Consolidated Financial Statements  
June 30, 2022 and 2021  
(dollars in thousands)

**(15) Net Assets**

Net assets consist of the following at June 30, 2022:

	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>	<u>Total</u>
<b>Endowment Funds</b>			
Instruction	\$ 499,764	\$ 712,750	\$ 1,212,514
Student aid	89,841	392,663	482,504
Program support	653,115	310,636	963,751
<b>Total endowment funds</b>	<u>1,242,720</u>	<u>1,416,049</u>	<u>2,658,769</u>
<b>Other Invested Funds</b>			
Property, plant and equipment, net	835,438	-	835,438
University designated	1,175,638	-	1,175,638
Purpose restrictions	-	29,844	29,844
Contributions receivable, net	-	79,094	79,094
Interests in perpetual funds held in trusts by others	-	61,002	61,002
Split-interest agreements	-	70,827	70,827
<b>Total other invested funds</b>	<u>2,011,076</u>	<u>240,767</u>	<u>2,251,843</u>
<b>Total net assets</b>	<u><u>\$ 3,253,796</u></u>	<u><u>\$ 1,656,816</u></u>	<u><u>\$ 4,910,612</u></u>

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
Notes to Consolidated Financial Statements  
June 30, 2022 and 2021  
(dollars in thousands)

Net assets consist of the following at June 30, 2021:

	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>	<u>Total</u>
<b>Endowment Funds</b>			
Instruction	\$ 592,464	\$ 807,679	\$ 1,400,143
Student aid	106,759	450,270	557,029
Program support	774,847	366,853	1,141,700
<b>Total endowment funds</b>	<u>1,474,070</u>	<u>1,624,802</u>	<u>3,098,872</u>
<b>Other Invested Funds</b>			
Property, plant and equipment, net	742,866	-	742,866
University designated	1,174,945	-	1,174,945
Purpose restrictions	-	30,240	30,240
Contributions receivable, net	-	81,774	81,774
Interests in perpetual funds held in trusts by others	-	73,039	73,039
Split-interest agreements	-	86,939	86,939
<b>Total other invested funds</b>	<u>1,917,811</u>	<u>271,992</u>	<u>2,189,803</u>
<b>Total net assets</b>	<u>\$ 3,391,881</u>	<u>\$ 1,896,794</u>	<u>\$ 5,288,675</u>

Roll forward of endowment net assets from June 30, 2020 to June 30, 2022:

	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>	<u>Total</u>
<b>Balance as of June 30, 2020</b>	\$ 1,110,247	\$ 1,157,620	\$ 2,267,867
Investment return, net	439,245	482,538	921,783
Gifts and transfers	(20,136)	43,672	23,536
Amounts appropriated for expenditure	(55,286)	(59,028)	(114,314)
<b>Balance as of June 30, 2021</b>	<u>1,474,070</u>	<u>1,624,802</u>	<u>3,098,872</u>
Investment return, net	(167,118)	(182,426)	(349,544)
Gifts and transfers	1,322	27,047	28,369
Amounts appropriated for expenditure	(65,554)	(53,374)	(118,928)
<b>Balance as of June 30, 2022</b>	<u>\$ 1,242,720</u>	<u>\$ 1,416,049</u>	<u>\$ 2,658,769</u>

**(16) Student Health Plan**

During the fiscal year ended June 30, 2018, the University established a self-funded student health insurance plan under Section 1124 of the New York State Insurance Law (NYSIL). The Student



**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

Health Insurance Plan (SHIP) provides health insurance coverage to students at the University. SHIP was developed especially for students (and their dependents) to provide access to convenient and comprehensive care that complements the quality of health services offered on campus. The plan year began on August 1, 2017.

The table below presents a summary of SHIP operations occurring during the University's fiscal years ending June 30:

	<u>July 1 - July 31</u> <u>(prior plan year)</u>	<u>Aug 1 - June 30</u> <u>(current plan year)</u>	<u>2022 Fiscal Year</u> <u>Total</u>	<u>July 1 - July 31</u> <u>(prior plan year)</u>	<u>Aug 1 - June 30</u> <u>(current plan year)</u>	<u>2021 Fiscal Year</u> <u>Total</u>
<b>Income:</b>						
Premium revenue	\$ 903	\$ 14,066	\$ 14,969	\$ 980	\$ 10,545	\$ 11,525
Interest income	-	2	2	-	1	1
<b>Total Income</b>	<b>903</b>	<b>14,068</b>	<b>14,971</b>	<b>980</b>	<b>10,546</b>	<b>11,526</b>
<b>Expenses:</b>						
Medical and prescription drug expense	933	13,128	14,061	897	9,839	10,736
Administrative fees	115	1,550	1,665	120	1,334	1,454
<b>Total Expenses</b>	<b>1,048</b>	<b>14,678</b>	<b>15,726</b>	<b>1,017</b>	<b>11,173</b>	<b>12,190</b>
<b>Net loss from health plan operations</b>	<b>\$ (145)</b>	<b>\$ (610)</b>	<b>\$ (755)</b>	<b>\$ (37)</b>	<b>\$ (627)</b>	<b>\$ (664)</b>

The University has established reserves with the amounts necessary to satisfy obligations of the plan. Based on an analysis and recommendation of a qualified actuary, and with the approval of New York State, the reserve for medical claims incurred but not reported (IBNR) is maintained at an amount not less than 18% of expected medical claims and 5% of expected pharmacy drug claims. In addition, a contingency reserve has been established for the purpose of satisfying unexpected obligations in the event of termination of the plan. During the current fiscal year, the contingency reserve was reclassified from a liability to reserve as part of net assets. The contingency reserve is maintained at an amount not less than 5% of the total current plan year premiums and is invested. New York State requires that the assets of the contingency reserve consist of certain investments of the types specified in Section 1404 of NYSIL. As of June 30, 2022, the contingency fund was invested in a money market fund, which is reported as cash and cash equivalents on the University's balance sheets and included within short-term investments in Note 6.

The changes in the unearned premiums and SHIP reserves during the fiscal year ended June 30, 2022 are presented below.

	<u>Unearned Premiums</u>	<u>IBNR Reserve</u>	<u>Contingency Reserve</u>
Balance as of July 1	\$ 1,489	\$ 1,704	\$ 576
Balance as of June 30	\$ 1,274	\$ 1,612	\$ 748
<b>Net Change</b>	<b>\$ 215</b>	<b>\$ 92</b>	<b>\$ (172)</b>

**UNIVERSITY OF ROCHESTER  
AND RELATED ENTITIES**  
**Notes to Consolidated Financial Statements**  
**June 30, 2022 and 2021**  
**(dollars in thousands)**

**(17) COVID-19**

In response to the disruptions that the COVID-19 pandemic caused in operations for institutions of higher education and health care organizations, on March 27, 2020, the Federal Government passed the Coronavirus Aid, Relief, and Economic Stimulus Act (CARES Act) which made funds available to the University through various provisions of the legislation. The following table summarizes the related impact on the University's Consolidated Financial Statements as of June 30, 2022 and 2021, and for the years then ended (in thousands):

<b>Consolidated Statements of Activities:</b>	<b>Line item</b>	<b>2022</b>	<b>2021</b>
CARES Act Provider Relief Funding (PRF)	Grant and contract revenue	\$ 21,984	\$ 124,071
CARES Act Higher Emergency Education Relief Funding (HEERF)	Grant and contract revenue	20,074	3,644
Paycheck Protection loans	Grant and contract revenue	-	12,245
<b>Balance Sheets:</b>	<b>Line item</b>	<b>2022</b>	<b>2021</b>
Deferral of Social Security taxes	Accounts payable and accrued expenses	\$ 46,010	\$ 85,936
CARES Act Provider Relief Funding (PRF)	Deferred revenue	435	500
CARES Act Higher Emergency Education Relief Funding (HEERF)	Deferred revenue	-	3,290
Centers for Medicare and Medicaid Services (CMS) Accelerated and Advanced Payments Program	Third-party settlements payable, net and other	17,126	170,571

**(18) Subsequent Events**

The University has performed an evaluation of subsequent events through October 26, 2022, the date on which the financial statements were issued and has concluded that there were no such events that require adjustments to the consolidated financial statements or disclosure in the notes to the consolidated financial statements.

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b><u>Student Financial Assistance Cluster:</u></b>			
<b>U. S. Department of Education Awards</b>			
<b>U. S. Department of Education Direct Awards</b>			
84.007		\$ 691,077	\$ -
84.033		1,591,025	-
84.038		9,132,918	-
84.038		-	-
		<u>9,132,918</u>	<u>-</u>
84.063		5,525,331	-
84.268		52,049,268	-
		<u>68,989,619</u>	<u>-</u>
<b>U. S. Department of Health and Human Services Awards</b>			
<b>U. S. Department of Health and Human Services Direct Awards</b>			
93.364		624,511	-
93.364		160,001	-
		<u>784,512</u>	<u>-</u>
<b>Total Student Financial Assistance Cluster</b>		<u>\$ 69,774,131</u>	<u>\$ -</u>
<b><u>Research and Development Program Cluster:</u></b>			
<b>U.S. Department of Agriculture Awards</b>			
<b>U.S. Department of Agriculture Direct Awards</b>			
10.310		100,370	-
		<u>100,370</u>	<u>-</u>
		100,370	-
<b>U.S. Department of Commerce Awards</b>			
<b>U.S. Department of Commerce Pass-Through Awards</b>			
11.619	FND AWD 1174466-2-94152	51,762	-
		<u>51,762</u>	<u>-</u>
<b>U.S. Department Of Defense Awards</b>			
<b>U.S. Army Direct Awards</b>			
12.RD		160,123	-
12.420		2,200,874	628,521
12.431		1,684,348	414,257
12.630		93,231	-
		<u>4,138,576</u>	<u>1,042,778</u>

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Research and Development Program Cluster, continued</b>				
<b>U.S. Army Pass-Through Awards</b>				
12.RD	UNIVERSITY OF SOUTHERN CALIFORNIA	SUBAWARD 72605819	\$ (23,128)	\$ -
12.RD	JOHNS HOPKINS UNIVERSITY	NA	(9,464)	-
12.RD	CRITICAL FREQUENCY DESIGN LLC	NA	11,036	-
12.420	UNIVERSITY OF SOUTHERN CALIFORNIA	SUBAWARD 69094337	1,261	-
12.420	UNIVERSITY OF SOUTHERN CALIFORNIA	SUBAWARD 69985229	22,195	-
12.420	DUKE UNIVERSITY	SUBAWARD 313000020	7,984	-
12.420	UNIVERSITY OF MICHIGAN	SUBK00014106	2,989	-
12.420	UNIVERSITY OF PENNSYLVANIA	SUBAWARD 582463	19,649	-
12.420	DENVER RESEARCH INSTITUTE	W81XWH-16-2-0004	245,485	-
12.420	MASSACHUSETTS EYE AND EAR	39383	4,120	-
12.431	AMYTHEST RESEARCH INC	NA	50,715	-
12.431	UNIVERSITY OF CENTRAL FLORIDA	244194	(1,012)	-
12.431	UNIVERSITY OF CALIFORNIA AT BERKELEY	00009856	148,402	-
12.630	UNIVERSITY OF PENNSYLVANIA	581854	28,916	-
	<b>Total U.S. Army Pass-Through Awards</b>		<u>509,148</u>	<u>-</u>
	<b>Total U.S. Army Awards</b>		<u>4,647,724</u>	<u>1,042,778</u>
<b>U.S. Air Force Direct Awards</b>				
12.RD	FA9550-21-1-0322		64,874	-
12.800	AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM		733,796	-
	<b>Total U.S. Air Force Direct Awards</b>		<u>798,670</u>	<u>-</u>
<b>U.S. Air Force Pass-Through Awards</b>				
12.RD	SUNY POLYTECHNIC INSTITUTE	AIM PHOTONICS	132,218	-
12.RD	SUNY POLYTECHNIC INSTITUTE	AIM - EWD - 2022	2,511	-
12.RD	CIRCLE OPTICS	FA864921P0209	10,220	-
12.RD	SYNOPSIS INC	W-911NF-17-9-0001	132,362	-
	<b>Total U.S. Air Force Pass-Through Awards</b>		<u>277,311</u>	<u>-</u>
	<b>Total U.S. Air Force Awards</b>		<u>1,075,981</u>	<u>-</u>
<b>U.S. Advanced Research Projects Agency Direct Awards</b>				
12.RD	HR00112090012		113,479	-
12.431	BASIC SCIENTIFIC RESEARCH		914,453	666,695
12.910	RESEARCH AND TECHNOLOGY DEVELOPMENT		774,863	237,953
	<b>Total U.S. Advanced Research Projects Agency Direct Awards</b>		<u>1,802,795</u>	<u>904,648</u>
<b>U.S. Advanced Research Projects Agency Pass-Through Awards</b>				
12.910	JOHNS HOPKINS UNIVERSITY	FA8750-19--0034	(30,738)	-
12.910	JOHNS HOPKINS UNIVERSITY	2003845219	75,216	-
12.910	STEVENS INSTITUTE OF TECHNOLOGY	2103299-02	71,438	-
12.910	CALTECH	S488617	531,869	-
12.910	UNIVERSITY OF PENNSYLVANIA	HR00112220013	318,006	-
	<b>Total U.S. Advanced Research Projects Agency Pass-Through Awards</b>		<u>965,791</u>	<u>-</u>
	<b>Total U.S. Advanced Research Projects Agency Awards</b>		<u>2,768,586</u>	<u>904,648</u>

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Research and Development Program Cluster, continued</b>				
<b>U.S. Intelligence Advanced Research Projects Agency Pass-Through Awards</b>				
12.RD	CARNEGIE MELLON	1990761- 449673	\$ 156,734	\$ -
	<b>Total U.S. Intelligence Advanced Research Projects Agency Pass-Through Awards</b>		<u>156,734</u>	<u>-</u>
<b>U.S. Navy Direct Awards</b>				
12.RD	N00173-17-P-3211		(3,080)	-
12.300	BASIC AND APPLIED SCIENTIFIC RESEARCH		2,203,255	822,445
	<b>Total U.S. Navy Direct Awards</b>		<u>2,200,175</u>	<u>822,445</u>
<b>U.S. Navy Pass-Through Awards</b>				
12.300	CLEMSON UNIVERSITY	2204-202-2023940	159,237	-
12.300	UNIVERSITY OF ILLINOIS AT URBANA	088813-16629	174,304	-
	<b>Total U.S. Navy Pass-Through Awards</b>		<u>333,541</u>	<u>-</u>
	<b>Total U.S. Navy Awards</b>		<u>2,533,716</u>	<u>822,445</u>
<b>U.S. Defense Threat Reduction Agency Direct Awards</b>				
12.351	HDTRA1-10-1-0025		(42)	-
12.351	HDTRA1-11-1-0052		(279)	-
	<b>Total U.S. Defense Threat Reduction Agency Direct Awards</b>		<u>(321)</u>	<u>-</u>
<b>U.S. Defense Threat Reduction Agency Pass-Through Awards</b>				
12.RD	JOHNS HOPKINS UNIVERSITY	2004758202	230,239	-
12.351	CALTECH	S395077	290,126	-
	<b>Total U.S. Defense Threat Reduction Agency Pass-Through Awards</b>		<u>520,365</u>	<u>-</u>
	<b>Total U.S. Defense Threat Reduction Agency Awards</b>		<u>520,044</u>	<u>-</u>
<b>U.S. Uniformed Services University of the Health Sciences Pass-Through Awards</b>				
12.750	THE GENEVA FOUNDATION	S-10558-01	558	-
	<b>Total U.S. Uniformed Services University of the Health Sciences Pass-Through Awards</b>		<u>558</u>	<u>-</u>
<b>U.S. Missile Defense Agency Pass-Through Awards</b>				
12.RD	L3 APPLIED TECHNOLOGIES	HQ0147-19-C-6504	21,128	-
12.RD	JOHNS HOPKINS UNIVERSITY	163880	803,737	-
	<b>Total U.S. Missile Defense Agency Pass-Through Awards</b>		<u>824,865</u>	<u>-</u>
	<b>Total U.S. Department of Defense Awards</b>		<u>12,528,208</u>	<u>2,769,871</u>
<b>National Aeronautics and Space Administration Awards</b>				
<b>National Aeronautics and Space Administration Direct Awards</b>				
43.001	SCIENCE		906,499	56,324
43.003	EXPLORATION		620,407	-
43.012	SPACE TECHNOLOGY		96,438	-
	<b>Total National Aeronautics and Space Administration Direct Awards</b>		<u>1,623,344</u>	<u>56,324</u>

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Research and Development Program Cluster, continued</b>				
<b>National Aeronautics and Space Administration Pass-Through Awards</b>				
43.RD	SPACE TELESCOPE SCIENCE INSTITUTE	HST-AR-14563.001-A	\$ 22,149	\$ -
43.RD	SPACE TELESCOPE SCIENCE INSTITUTE	HST-GO-16493.002-A	24,863	-
43.RD	AMYTHEST RESEARCH INC	80NSSC21C0099	26,000	-
43.RD	JACOBS SPACE EXPLORATION GROUP	PO21N0300	22,021	-
43.001	RENSSELAER POLYTECHNIC INSTITUTE	A19-0117-S002	58,930	-
43.001	JET PROPULSION LAB	1573311	2,583	-
43.001	JET PROPULSION LAB	1616833	1,191	-
43.001	SPACE TELESCOPE SCIENCE INSTITUTE	STSCI 51464	43,599	-
43.008	NATIONAL INSTITUTE OF AEROSPACE	C21-202054-UR	152,806	-
43.008	CORNELL UNIVERSITY	76156-10493	10,000	-
	<b>Total National Aeronautics and Space Administration Pass-Through Awards</b>		<u>364,142</u>	<u>-</u>
	<b>Total National Aeronautics and Space Administration Awards</b>		<u>1,987,486</u>	<u>56,324</u>
<b>National Science Foundation Awards</b>				
<b>National Science Foundation Direct Awards</b>				
47.041	ENGINEERING GRANTS		2,464,463	484,443
47.049	MATHEMATICAL AND PHYSICAL SCIENCES		7,245,019	953,327
47.050	GEOSCIENCES		1,328,313	65,200
47.070	COMPUTER AND INFORMATIONAL SCIENCE AND ENGINEERING		2,720,626	-
47.074	BIOLOGICAL SCIENCES		1,486,410	-
47.075	SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES		856,298	-
47.076	EDUCATION AND HUMAN RESOURCES		3,836,644	341,639
47.079	OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING		204,282	-
47.083	INTEGRATIVE ACTIVITIES		401,976	288,039
	<b>Total National Science Foundation Direct Awards</b>		<u>20,544,031</u>	<u>2,132,648</u>
<b>National Science Foundation Pass-Through Awards</b>				
47.RD	LIGHTTOP TECH CORP	NA	8,436	-
47.041	UNIVERSITY OF NEW MEXICO	433652-871C	22,812	-
47.041	CORNELL UNIVERSITY	79546-10790	55,203	-
47.049	UNIVERSITY OF ILLINOIS AT URBANA	097001-17605	92,527	-
47.049	UNIVERSITY OF WISCONSIN AT MADISON	PHY-1913607	59,077	-
47.049	CORNELL UNIVERSITY	80497-10952	91,934	-
47.050	FERMI NATIONAL ACCELERATOR LAB	EAR-1818654	49,806	-
47.070	UNIVERSITY OF SOUTHERN CALIFORNIA	2124453	59,685	-
47.070	GEORGIA INSTITUTE OF TECHNOLOGY	AWD-000309-G1	25,123	-
47.070	COMPUTING RESEARCH ASSOCIATES	CIF2020-UR-36	125,753	-
47.074	TENNESSEE STATE UNIVERSITY	33277-19.0518	59,907	-
47.074	UNIVERSITY OF ARIZONA	465324	2,917	-
47.074	CORNELL UNIVERSITY	91778-20442	11,924	-
47.076	UNIVERSITY OF WISCONSIN AT MADISON	0000000542	201,242	-
47.076	EDUCATION DEVELOPMENT CENTER INC	2050641	21,781	-
47.083	UNIVERSITY OF CALIFORNIA AT SANTA BARBARA	KK2237	44,844	-
	<b>Total National Science Foundation Pass-Through Awards</b>		<u>932,971</u>	<u>-</u>
	<b>Total National Science Foundation Awards</b>		<u>21,477,002</u>	<u>2,132,648</u>

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Research and Development Program Cluster, continued</b>				
<b>Environmental Protection Agency</b>				
<b>Environmental Protection Agency Pass-Through Awards</b>				
66.CTR	EMORY UNIVERSITY	A572658	\$ 51,629	\$ -
	<b>Total Environmental Protection Agency Pass-Through Awards</b>		<u>51,629</u>	<u>-</u>
<b>U.S. Department of Energy Awards</b>				
<b>U.S. Department of Energy Direct Awards</b>				
81.049	OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM		8,352,140	749,401
81.112	STEWARDSHIP SCIENCE GRANT PROGRAM		79,279,453	1,834,210
81.135	ADVANCED RESEARCH PROJECTS - ENERGY		2,205,940	3,584
	<b>Total U.S. Department of Energy Direct Awards</b>		<u>89,837,533</u>	<u>2,587,195</u>
<b>U.S. Department of Energy Pass-Through Awards</b>				
81.RD	LAWRENCE BERKELEY NATIONAL LAB	B603004	(12,693)	-
81.RD	LAWRENCE BERKELEY NATIONAL LAB	7633925	12,600	-
81.RD	LOGOS TECHNOLOGIES INC	SUB-370-LLE	87	-
81.RD	SCHAFFER CORP	SC-1132A-01	(7,094)	-
81.RD	FERMI NATIONAL ACCELERATOR LAB	655186	134,863	-
81.RD	FERMI NATIONAL ACCELERATOR LAB	665864	46,176	-
81.RD	FERMI NATIONAL ACCELERATOR LAB	686897	38,252	-
81.RD	LOS ALAMOS NATIONAL LAB	533111-MOD002	1,066	-
81.RD	LAWRENCE LIVERMORE NATIONAL LAB	B648786	18,257	-
81.RD	LAWRENCE LIVERMORE NATIONAL LAB	B637954	63,209	-
81.RD	LAWRENCE LIVERMORE NATIONAL LAB	B634561	(1,224)	-
81.RD	LAWRENCE LIVERMORE NATIONAL LAB	B629070	(1,622)	-
81.RD	LAWRENCE LIVERMORE NATIONAL LAB	B629036	8,811	-
81.RD	LAWRENCE LIVERMORE NATIONAL LAB	B629431	1,475	-
81.RD	LAWRENCE LIVERMORE NATIONAL LAB	B630618	(32,994)	-
81.RD	LAWRENCE LIVERMORE NATIONAL LAB	B647770	122,824	-
81.RD	LOS ALAMOS NATIONAL LAB	482526	348,906	-
81.RD	LOS ALAMOS NATIONAL LAB	20345	11,986	-
81.RD	PACIFIC NORTHWEST NATIONAL LABORATORY	499712	135,520	-
81.RD	PACIFIC NORTHWEST NATIONAL LABORATORY	565314	253,845	-
81.RD	PACIFIC NORTHWEST NATIONAL LABORATORY	483942	46,976	-
81.RD	BRIMROSE TECHNOLOGY CORP	BTC-UR	35,832	-
81.RD	BRIMROSE TECHNOLOGY CORP	22473	25,128	-
81.RD	UNIVERSITY OF CALIFORNIA AT SAN DIEGO	132591903	100,593	-
81.RD	STANFORD UNIVERSITY	217663	178,069	-
81.RD	SANDIA NATIONAL LABS	PO 2051292	5,832	-
81.RD	SANDIA NATIONAL LABS	PO 2300100	131,706	-
81.RD	SANDIA NATIONAL LABS	PO 2332811	49,878	-
81.RD	SANDIA NATIONAL LABS	PO 2211693	15,653	-
81.049	PRINCETON UNIVERSITY	SUB0000391	12,127	-
81.049	SYDOR INSTRUMENTS LLC	DE-SC0021792	60,817	-

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Research and Development Program Cluster, continued</b>				
81.049	STATE UNIVERSITY OF NEW YORK AT STONEYBROOK	86736/115849/2	\$ 39,276	\$ -
81.049	RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AT BUFFALO	R1144501	2,586	-
81.049	AUBURN UNIVERSITY	15-PHYS-211628-UR	8,265	-
81.049	STATE UNIVERSITY OF NEW YORK AT STONEYBROOK	86368/1157489/2	36,719	-
81.112	WASHINGTON STATE UNIVERSITY	117556-G003471	(139)	-
81.112	UNIVERSITY OF CHICAGO	AWD100444	(28,016)	-
81.113	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	DENA0003868	88,110	-
	<b>Total U.S. Department of Energy Pass-Through Awards</b>		<u>1,951,662</u>	<u>-</u>
	<b>Total U.S. Department of Energy Awards</b>		<u>91,789,195</u>	<u>2,587,195</u>
<b>U.S. Department of Health and Human Services Awards</b>				
<b>U.S. Department of Health and Human Services Direct Awards</b>				
93.RD	CONTRACT - HHSN272201400005		1,866,656	1,185,046
	COVID 19 - SECTION 223 DEMONSTRATION PROGRAMS TO IMPROVE COMMUNITY MENTAL			
93.829	HEALTH SERVICES		1,769,355	-
<b>National Institutes of Health Direct Awards</b>				
93.RD	75N98019P03295		(612)	-
93.077	FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH		166,491	12,527
93.113	BIOLOGICAL RESPONSE TO ENVIRONMENTAL HEALTH HAZARDS		6,367,158	661,758
93.121	ORAL DISEASES AND DISORDERS RESEARCH		4,379,999	316,160
93.172	HUMAN GENOME RESEARCH		78,957	-
93.173	RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS		5,812,502	94,472
93.186	HEALTH RESOURCES AND SERVICES ASSOCIATION		267,932	-
93.213	RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH		409,200	-
93.242	MENTAL HEALTH RESEARCH GRANTS		5,778,456	1,708,704
93.243	SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE		532,863	16,313
93.273	ALCOHOL RESEARCH PROGRAMS		1,471,361	181,702
93.279	DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS		2,633,390	292,040
93.286	DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH		947,347	166,485
93.307	MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH		671,492	99,642
93.310	TRANS-NIH RESEARCH SUPPORT		5,375,393	1,519,740
93.350	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES		8,869,173	24,878
93.351	RESEARCH INFRASTRUCTURE PROGRAMS		302,588	-
93.353	21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT		1,042,508	18,804
93.361	NURSING RESEARCH		1,307,951	71,883
93.393	CANCER CAUSE AND PREVENTION RESEARCH		1,429,805	237,628
93.394	CANCER DETECTION AND DIAGNOSIS RESEARCH		247,134	14,490
93.395	CANCER TREATMENT RESEARCH		5,284,230	500,851
93.396	CANCER BIOLOGY RESEARCH		1,504,713	10,728
93.398	CANCER RESEARCH MANPOWER		1,071,670	-
93.399	CANCER CONTROL		6,454,055	-
93.837	CARDIOVASCULAR DISEASES RESEARCH		9,319,276	157,384
93.838	LUNG DISEASES RESEARCH		6,735,720	302,444
93.839	BLOOD DISEASES AND RESOURCES RESEARCH		1,005,848	306,827
93.840	TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART LUNG BLOOD DISEASES AND SLEEP DISORDERS		757,645	271,873
93.846	ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES EXTRAMURAL RESEARCH		6,578,801	802,638

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards



**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Research and Development Program Cluster, continued</b>				
93.847	DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH		\$ 3,706,737	\$ 423,076
93.853	EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCE AND NEUROLOGICAL DISORDERS		17,590,241	4,180,485
93.855	ALLERGY, IMMUNOLOGY, AND TRANSPLANTATION RESEARCH		19,540,129	2,114,125
93.859	BIOMEDICAL RESEARCH AND RESEARCH TRAINING		14,265,229	523,812
93.865	CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH		5,358,055	462,908
93.866	AGING RESEARCH		16,165,087	2,219,062
93.867	VISION RESEARCH		10,084,688	766,758
93.989	SENIOR INTERNATIONAL FELLOWSHIPS		232,779	59,337
	<b>Total National Institutes of Health Direct Awards</b>		<u>173,745,991</u>	<u>18,539,534</u>
<b>Food and Drug Administration Direct Awards</b>				
93.103	FOOD AND DRUG ADMINISTRATION RESEARCH		478,260	235,012
	<b>Total Food and Drug Administration Direct Awards</b>		<u>478,260</u>	<u>235,012</u>
<b>Centers for Disease Control and Prevention Direct Awards</b>				
93.135	CENTER FOR RESEARCH AND DEMONSTRATION FOR HEALTH PROMOTION AND DISEASE PREVENTION		1,098,355	17,819
93.185	IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFO AND EDUCATION TRAINING		1,823,458	322,022
	<b>Total Centers for Disease Control and Prevention Direct Awards</b>		<u>2,921,813</u>	<u>339,841</u>
<b>Health Resources and Services Administration Direct Awards</b>				
93.059	TRAINING IN GENERAL, PEDIATRIC, AND PUBLIC HEALTH DENTISTRY		336,687	-
93.250	GERIATRIC ACADEMIC CAREER AWARDS		78,838	-
93.884	GRANTS FOR TRAINING IN PRIMARY CARE MEDICINE AND DENTISTRY		208,728	8,541
93.912	RURAL HEALTHCARE SERVICES OUTREACH RURAL HEALTH NETWORK DEVELOPMENT		3,498,628	149,036
93.924	RYAN WHITE HIV/AIDS DENTAL REIMBURSEMENT AND COMMUNITY BASED DENTAL PARTNERSHIP GRANTS		31,904	-
93.976	INTERNATIONAL RESEARCH AND RESEARCH TRAINING		334,245	-
	<b>Total Health Resources and Services Administration Direct Awards</b>		<u>4,489,030</u>	<u>157,577</u>
<b>Agency for Healthcare Research and Quality Direct Awards</b>				
93.226	RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES		296,591	26,173
	<b>Total Agency for Healthcare Research and Quality Direct Awards</b>		<u>296,591</u>	<u>26,173</u>
<b>IMMED Office of the Secretary of Health and Human Services Direct Awards</b>				
93.826	CLOSING THE GAP BETWEEN STANDARDS DEVELOPMENT AND IMPLEMENTATION		524,035	226,775
	<b>Total IMMED Office of the Secretary of Health and Human Services Direct Awards</b>		<u>524,035</u>	<u>226,775</u>
	<b>Total U.S. Department of Health and Human Services Direct Awards</b>		<u>186,091,731</u>	<u>20,709,958</u>
<b>U.S. Department of Health and Human Services Pass-Through Awards</b>				
93.RD	REGENERON PHARMACEUTICALS INC	R10933-10987-COV-2066	\$ 40,148	\$ -
93.RD	DUKE UNIVERSITY	HHSO100201400002I	162,822	-
93.RD	OREGON STATE UNIVERSITY	J2423A-A	113,455	-
93.RD	OREGON HEALTH & SCIENCE UNIVERSITY	SWOG	32,826	-
93.RD	RESEARCH FOUNDATION FOR MENTAL HYGIENE INC	155842	27,929	-
93.RD	RESEARCH FOUNDATION FOR MENTAL HYGIENE INC	156367	17,648	-
93.RD	NEW YORK STATE	CMS	65,554	-
93.RD	ACADEMIC PEDIATRIC ASSOCIATION	6NH23IP000950-05-00	(820)	-

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Research and Development Program Cluster, continued</b>				
<b>National Institutes of Health Pass-Through Awards</b>				
93.RD	MASSACHUSETTS GENERAL HOSPITAL	A5332 & A5333s	\$ 81,312	\$ -
93.RD	ARGENTUM MEDICAL	NA	188,289	-
93.RD	LEIDOS BIOMEDICAL RESEARCH INC	22CTA-DM0003	115,322	-
93.RD	DUKE UNIVERSITY	URM99	2,435	-
93.RD	RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AT ALBANY	18-37-80851	(431)	-
93.RD	CHARLES RIVER ANALYTICS INC	SC1725902	32,119	-
93.RD	CHILDRENS HOSPITAL OF PHILADELPHIA	NA	5,675	-
93.RD	FRED HUTCHINSON CANCER RESEARCH CENTER	965946	44,257	-
93.RD	LITRON LABORATORIES	NA	(89)	-
93.RD	UNIVERSITY OF GEORGIA RESEARCH FOUNDATION	SUB00002155-3A	157,529	-
93.RD	UNIVERSITY OF GEORGIA RESEARCH FOUNDATION	SUB00002583-01	96,010	-
93.RD	UNIVERSITY OF PITTSBURGH	ACTIV-4B	21,798	-
93.RD	CITY OF HOPE	3000220483	24,870	-
93.RD	MT SINAI SCHOOL OF MEDICINE	0258-A703-4609	124,482	-
93.RD	MT SINAI SCHOOL OF MEDICINE	0258-A707-4609	361,833	-
93.RD	NATIONAL DISEASE RESEARCH EXCHANGE AT THREE PARK	141147	42,637	-
93.RD	ROSWELL PARK CANCER CENTER	NA	5,816	-
93.077	HEALTH RESEARCH INC (HRI)	U54CA228110	1,136,053	-
93.077	UNIVERSITY OF SOUTHERN CALIFORNIA	138628897	13,792	-
93.113	OREGON STATE UNIVERSITY	P0525-A-A	33,007	-
93.113	SIMPORE INC	SEA-PUR	(1,379)	-
93.113	SCIENCE TAKE-OUT LLC	R42ES023706	11,326	-
93.113	RESEARCH FOUNDATION FOR MENTAL HYGIENE	140406	153,946	-
93.113	UNIVERSITY OF PITTSBURGH	0059250(131639-2)	63,491	-
93.113	MT SINAI SCHOOL OF MEDICINE	0255-8271-4609	363	-
93.113	RUTGERS, THE STATE UNIVERSITY	897022	47,971	-
93.121	RUTGERS, THE STATE UNIVERSITY	UG3DE028860	17,101	-
93.121	RUTGERS, THE STATE UNIVERSITY	25108157	351,402	-
93.121	NEW YORK UNIVERSITY	R01DE027981	45,353	-
93.121	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000412838-006	3,053	-
93.121	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000412838-036	568,971	-
93.121	UNIVERSITY OF ALABAMA AT BIRMINGHAM	0004128-38-024	82,583	-
93.121	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000412838-081	98,936	-
93.121	SCRIPPS RESEARCH INSTITUTE	5-54609	41,871	-
93.121	UNIVERSITY OF PENNSYLVANIA	4130135	13,393	-
93.136	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5116328	34,056	-
93.136	HEALTH RESEARCH INC (HRI)	6215-02	885	-
93.136	HEALTH RESEARCH INC (HRI)	6215-03	17,820	-
93.137	AMERICAN COLLEGE OF RHEUMATOLOGY INC	7/1/18 MIMICT	6,030	-
93.137	AMERICAN COLLEGE OF RHEUMATOLOGY INC	OMH-TIMELY	602	-
93.142	SIMPORE INC	MP2-UR092021	43,693	-
93.172	DAHLIA BIOSCIENCES INC	001	3,241	-
93.173	THE JOHN B PIERCE LABORATORY INC	290-A	11,406	-
93.173	BOSTON COLLEGE	5106711-02	31,505	-
93.173	SYRACUSE UNIVERSITY	32388-06204-S01	2,941	-

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Research and Development Program Cluster, continued</b>				
93.173	DREXEL UNIVERSITY	800198	\$ 32,613	\$ -
93.213	CHILDREN'S HOSPITAL OF BOSTON	GENFD0001723702	445,817	-
93.213	VETERANS HEALTH RESEARCH INSTITUTE OF CENTRAL NY INC	VHRI-UofR-352	11,504	-
93.226	AMERICAN COLLEGE OF SURGEONS	6646GP001URMC	150,818	-
93.226	COLUMBIA UNIVERSITY	2(GG017698-01)	10,750	-
93.242	INDIANA UNIVERSITY	8817-UR	57,046	-
93.242	HARVARD UNIVERSITY	149663.5115904.0003	18,385	-
93.242	UNIVERSITY OF CHICAGO	SUB00000288	65,782	-
93.242	YALE UNIVERSITY	GR5106869	8,267	-
93.242	PRINCETON UNIVERSITY	SUB0000488	7,426	-
93.242	RUTGERS, THE STATE UNIVERSITY	1320	15,807	-
93.242	VETERANS BIO-MED RESEARCH INSTITUTE	1R56MH121555-Sub01	9,477	-
93.242	UNIVERSITY OF PITTSBURGH	132532-1	31,515	-
93.242	MICHIGAN STATE UNIVERSITY	RC108066UR	15,297	-
93.242	MICHIGAN STATE UNIVERSITY	RC112111C	28,759	-
93.242	WASHINGTON UNIVERSITY AT SAINT LOUIS	WU-22-0366/PO ST00006079	8,215	-
93.242	FLORIDA INTERNATIONAL UNIVERSITY	454	27,861	-
93.242	UNIVERSITY OF MARYLAND	3000559 PO 1000005523	24,961	-
93.243	CHILDREN'S INSTITUTE INC	NA	158,802	-
93.243	GALLAUDET UNIVERSITY	783-UR	21,617	-
93.273	UNIVERSITY OF ARKANSAS	G190120995	314,503	-
93.279	CASE WESTERN RESERVE UNIVERSITY	RES516509	58,979	-
93.279	YALE UNIVERSITY	GR112840	151,894	-
93.279	JOHNS HOPKINS UNIVERSITY	2002914003	(23)	-
93.286	UNIVERSITY OF ILLINOIS	RC104170UR	57,131	-
93.286	RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AT BUFFALO	R1219526	20,124	-
93.286	NORTHWESTERN UNIVERSITY	60058448 UR	100,348	-
93.307	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5113789	129,657	-
93.307	AGILE HEALTH INC	URMC-2R42MD010318-02A1	307,678	-
93.310	JOHNS HOPKINS UNIVERSITY	2004442514	33,812	-
93.310	DUKE UNIVERSITY	A03-5217	207,315	-
93.310	UNIVERSITY OF PITTSBURGH	AWD00004824	70,282	-
93.310	UNIVERSITY OF CALIFORNIA AT SAN DIEGO	111593290	14,824	-
93.310	THE BRIGHAM AND WOMEN'S HOSPITAL INC	119919	138,112	-
93.310	NEW YORK UNIVERSITY SCHOOL OF MEDICINE	M190185374	80,052	-
93.310	UNIVERSITY OF WASHINGTON	UWSC9401 BPO18354	182,830	-
93.310	UNIVERSITY OF CALIFORNIA AT SAN DIEGO	130886117	79,956	-
93.310	NEW YORK UNIVERSITY	19-AO-00-1003237	148,960	-
93.310	ALBERT EINSTEIN COLLEGE OF MEDICINE	706691	341,339	-
93.310	NEW YORK UNIVERSITY	iB00269690	(82)	-
93.350	UNIVERSITY OF MICHIGAN	SUBK00008544	79,507	-
93.350	DYSTONIA COALITION	NA	(806)	-
93.350	UNIVERSITY OF PITTSBURGH	AWD00000243 (132627-50)	(3,000)	-
93.350	THE ROCKEFELLER UNIVERSITY	SUB00000120	108,729	-

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Research and Development Program Cluster, continued</b>				
93.359	THE MARY IMOGENE BASSETT HOSPITAL	NA	\$ 46,214	\$ -
93.361	GLOBAL INSTRUMENTATION LLC	NIHGRANTCM	120,080	-
93.361	ROCHESTER INSTITUTE OF TECHNOLOGY	32559-01	179,180	-
93.361	UNIVERSITY OF CALIFORNIA AT IRVINE	FY20.1019.001	8,340	-
93.393	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000527577-SC007	23,012	-
93.393	UNIVERSITY OF ALABAMA AT BIRMINGHAM	00532274-SC002	60,368	-
93.393	TUFTS UNIVERSITY	5022532_SERV	9,147	-
93.393	RUTGERS, THE STATE UNIVERSITY	1388 PO 1366180	39,003	-
93.393	STANFORD UNIVERSITY	62387300-138175	53,931	-
93.393	HEALTH RESEARCH INC (HRI)	270-01	32,200	-
93.393	HEALTH RESEARCH INC (HRI)	270-01	483,039	-
93.393	MASSACHUSETTS GENERAL HOSPITAL	237365	27,672	-
93.393	MAYO CLINIC	66696209	156,374	-
93.393	DARTMOUTH-HITCHCOCK CLINIC	GC10035-00-02	(642)	-
93.393	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	1647GVA215	20,859	-
93.393	RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AT BUFFALO	R1136979	(775)	-
93.393	UNIVERSITY OF PENNSYLVANIA	576656	17,415	-
93.394	THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	3001595118	24,874	-
93.394	UNIVERSITY OF ILLINOIS AT URBANA	3001145995	(45,713)	-
93.394	CEDARS SINAI MEDICAL CENTER	085404-16517	6,500	-
93.395	UNIVERSITY OF SOUTHERN CALIFORNIA	SCON-00002445	27,275	-
93.395	CHILDRENS HOSPITAL OF PHILADELPHIA	20292668	27,000	-
93.395	ROCHESTER INSTITUTE OF TECHNOLOGY	32751-01	4,173	-
93.395	PUBLIC HEALTH INSTITUTE	AR04580	784	-
93.395	OREGON HEALTH & SCIENCE UNIVERSITY	9009627	68,722	-
93.395	OREGON HEALTH & SCIENCE UNIVERSITY	1013080	481,852	-
93.395	H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC	10-16914-99-01-SA-02	194,744	-
93.395	HEALTH RESEARCH INC (HRI)	330-01	294,635	-
93.395	SYNTRIX BIOMETRICS	SX682-Melanoma-101	6,908	-
93.395	UNIVERSITY OF ARKANSAS	FP54643	30,016	-
93.395	MAYO CLINIC	UOR-227243	6,167	-
93.396	HEALTH RESEARCH INC (HRI)	410-01	27,349	-
93.397	WASHINGTON UNIVERSITY AT SAINT LOUIS	WU-17-347/WU-18-121/WU-19-64	(2,402)	-
93.397	DANA FARBER CANCER INSTITUTE	1173610	2,453	-
93.583	CASE WESTERN RESERVE UNIVERSITY	RES516960	23,215	-
93.630	NEW YORK STATE DEVELOPMENTAL DISABILITIES PLANNING	DDP01-T00004GG-1100200	27,464	-
93.788	RESEARCH FOUNDATION FOR MENTAL HYGIENE	147959	(31)	-
93.837	DUKE UNIVERSITY	4550617360	7,140	-
93.837	THOMAS JEFFERSON UNIVERSITY	080-18007-S43701	13,879	-
93.837	ALBERT EINSTEIN COLLEGE OF MEDICINE	706801	11,437	-
93.837	STATE UNIVERSITY OF NEW YORK AT BUFFALO	R1130653	100,586	-
93.837	UNIVERSITY OF MICHIGAN	SUBK00011704	88,615	-
93.837	COLUMBIA UNIVERSITY	10(GG015243-01)	2,783	-
93.837	COLUMBIA UNIVERSITY	2(GG017860-01)	29,548	-
93.837	FLORIDA INTERNATIONAL UNIVERSITY	800010643-01UG	122,589	-
93.837	NEW YORK UNIVERSITY SCHOOL OF MEDICINE	ISCHEMIA	4,397	-
93.837	PERFUSIO CORPORATION	11666sc	39,746	-

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Research and Development Program Cluster, continued</b>				
93.837	CHILDRENS HOSPITAL OF LOS ANGELES	113047	\$ 96,914	\$ -
93.837	YALE UNIVERSITY	CON-80001391	(1)	-
93.837	THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA	5 R01 AG058746-03	69,388	-
93.837	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	109363	(63,849)	-
93.837	THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	3001421865	80,191	-
93.837	JOHNS HOPKINS UNIVERSITY	2003505981	29,559	-
93.837	NEW YORK UNIVERSITY SCHOOL OF MEDICINE	16-A0-00-006568-01	(15,314)	-
93.837	CHILDRENS HOSPITAL OF PHILADELPHIA	963030-RSUB	279,887	-
93.837	UNIVERSITY OF COLORADO DENVER	FY21.226.001	998,134	-
93.838	DUKE UNIVERSITY	ILDI-SAFE A035364 (SPS-269060)	12,979	-
93.838	CHILDREN'S HOSPITAL MEDICAL CENTER	OS0002264/Project 311013	26,635	-
93.838	UNIVERSITY OF COLORADO DENVER	FY22.1126.039	170,512	-
93.838	VIRGINIA COMMONWEALTH UNIVERSITY	FP00010985_SA001	14,461	-
93.838	UNIVERSITY OF RHODE ISLAND	7137503	49,241	-
93.838	UNIVERSITY OF MICHIGAN	SUBK00013182	18,248	-
93.838	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	700206-0720-00	10,644	-
93.838	UNIVERSITY OF CINCINNATI	011995-002	(6,838)	-
93.838	MASSACHUSETTS GENERAL HOSPITAL	234261	4,425	-
93.838	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5111586	48,373	-
93.838	THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	SA0002146	65,177	-
93.838	RHODE ISLAND HOSPITAL	7137503	127,163	-
93.838	ALBERT EINSTEIN COLLEGE OF MEDICINE	P0874088	21,629	-
93.839	NATIONAL MARROW DONOR PROGRAM	1101	22,222	-
93.839	WASHINGTON UNIVERSITY AT SAINT LOUIS	WU-14-187	(8,919)	-
93.839	MEDICAL COLLEGE OF WISCONSIN	6075967	256,241	-
93.839	UNIVERSITY OF WASHINGTON	UWSC10043; BPO#26428	4	-
93.839	MT SINAI SCHOOL OF MEDICINE	0255-E001-4609	252,166	-
93.846	UNIVERSITY OF CALIFORNIA AT IRVINE	2021-1474	58,651	-
93.846	UNIVERSITY OF WASHINGTON	UWSC10834	(1,224)	-
93.846	UNIVERSITY OF WASHINGTON	UWSC10834 BPO60357	77,882	-
93.846	BAYLOR COLLEGE OF MEDICINE	NA	(8,234)	-
93.846	THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	SA0002380	35,611	-
93.846	BAYLOR COLLEGE OF MEDICINE	7000000616	270,069	-
93.846	BOSTON UNIVERSITY	4500003634	56,758	-
93.846	HOSPITAL FOR SPECIAL SURGURY	001	66,976	-
93.846	SUNY UPSTATE MEDICAL UNIVERSITY	1162484-88632	87,347	-
93.846	THE BRIGHAM AND WOMEN'S HOSPITAL INC	117592	2,765	-
93.846	UNIVERSITY OF COLORADO DENVER	FY19.957.003/2-5-A7507	153,841	-
93.846	MASSACHUSETTS GENERAL HOSPITAL	NN109 #231203	83,888	-
93.847	UNIVERSITY OF CALIFORNIA AT IRVINE	1560BXA870	309	-
93.847	MT SINAI SCHOOL OF MEDICINE	0255-D471-4609	73,241	-
93.847	CORNELL UNIVERSITY	88231-20830	89,468	-
93.847	UNIVERSITY OF TEXAS AT DALLAS	2008270	99,162	-
93.847	UNIVERSITY OF MICHIGAN	SUBK00010073	50,331	-
93.847	THE CHILDREN'S HOSPITAL OF PHILADELPHIA	3301820719	3,476	-
93.847	CARNEGIE MELLON UNIVERSITY	1090558-408559	30,383	-

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Research and Development Program Cluster, continued</b>				
93.847	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000520376-005	\$ 15,261	\$ -
93.847	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	5114092	140,060	-
93.847	THE BRIGHAM AND WOMEN'S HOSPITAL INC	114959	(803)	-
93.847	UNIVERSITY OF NEVADA	UNR-13-14	(1,507)	-
93.853	UNIVERSITY OF CINCINNATI	012043-134237	14,700	-
93.853	BROWN UNIVERSITY	1569	55,718	-
93.853	JOHNS HOPKINS UNIVERSITY	NA	146,239	-
93.853	JOHNS HOPKINS UNIVERSITY	2003962210	136,389	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	226396	74,500	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	NeuroNEXT	6,288	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	235486	132,569	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	235486	369,927	-
93.853	CASE WESTERN RESERVE UNIVERSITY	NA	321	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	235486	72,217	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	NN110	35,049	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	238257	55,367	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	237960	246,625	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	EPPIC-Net Task Order #01	100	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	239694	41,122	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	239655	11,458	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	226396	14,286	-
93.853	UNIVERSITY OF MICHIGAN	SUBK11701CSPR-002	12,714	-
93.853	SIMULATED INANIMATE MODELS LLC	1R41NS115308-01	3,021	-
93.853	NORTHWESTERN UNIVERSITY	60036745UR	117,768	-
93.853	UNIVERSITY OF CINCINNATI	011337-134237	37,900	-
93.853	FRED HUTCHINSON CANCER RESEARCH CENTER	00010002908	(1)	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	232828	38,797	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	230754(NN108)	16,101	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	235486	28,661	-
93.853	BIOSENSICS LLC	1 R44 NS103648-01	(1,645)	-
93.853	UNIVERSITY OF MICHIGAN	SUBK11701CSPR-002	86,274	-
93.853	FRED HUTCHINSON CANCER RESEARCH CENTER	1002908	13	-
93.853	VIRGINIA COMMONWEALTH UNIVERSITY	FP00008389-SA003	3,621	-
93.853	UNIVERSITY OF CALIFORNIA AT SAN DIEGO	703866	21,632	-
93.853	UNIVERSITY OF MINNESOTA	A008261601	91,823	-
93.853	UNIVERSITY OF IOWA	S01110-01	(21)	-
93.853	FRED HUTCHINSON CANCER RESEARCH CENTER	0000959964	(2,656)	-
93.853	KENNEDY KRIEGER INSTITUTE	NA	(4)	-
93.853	INDIANA UNIVERSITY	8908	23,052	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	228758	92,081	-
93.853	MASSACHUSETTS GENERAL HOSPITAL	239654	771	-
93.853	UNIVERSITY OF IOWA	S00443-01	201,622	-
93.853	UNIVERSITY OF MIAMI	SPC-001074	46,343	-
93.853	FRED HUTCHINSON CANCER RESEARCH CENTER	0000921214	(1,887)	-
93.853	UNIVERSITY OF TEXAS AT AUSTIN	UTA20-001703	57,620	-
93.853	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	1713 G ZA659	100,215	-
93.853	UNIVERSITY OF CINCINNATI	010785-134237	4,757	-

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Research and Development Program Cluster, continued</b>				
93.853	UNIVERSITY OF CINCINNATI	012043-134237	\$ 10,334	\$ -
93.855	NATIONAL JEWISH HEALTH	2020096504	(40,987)	-
93.855	NATIONAL JEWISH HEALTH	2020096904	96,087	-
93.855	MEDICAL UNIVERSITY OF SOUTH CAROLINA	MUSC14-035	(758)	-
93.855	JOHNS HOPKINS UNIVERSITY	2003244333	(8,560)	-
93.855	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	9307SC	(18,470)	-
93.855	FRED HUTCHINSON CANCER RESEARCH CENTER	966653	30	-
93.855	KARYOPHARM THERAPEUTICS INC	8016	(154,263)	-
93.855	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	9875SC	3	-
93.855	BRIGHAM & WOMENS HOSPITAL	FUND 114342	(2,168)	-
93.855	COLUMBIA UNIVERSITY	23(GG011896-49)	(4,012)	-
93.855	CORNELL UNIVERSITY	80863-10990	49,448	-
93.855	NATIONAL JEWISH HEALTH	20099304	(6,844)	-
93.855	NATIONAL JEWISH HEALTH	20098204	19,233	-
93.855	THE UNIVERSITY OF TEXAS HEALTH SCIENCES CENTER AT SAN ANTONIO	165103/165101	77,940	-
93.855	ST JUDE MEDICAL	112525040-8077025	337,155	-
93.855	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	560BWA788	(2,071)	-
93.855	FAMILY HEALTH INTERNATIONAL (FHI 360)	21000560	85,900	-
93.855	WASHINGTON UNIVERSITY AT SAINT LOUIS	WU-21-405-MOD-2	51,472	-
93.855	CORNELL UNIVERSITY	90844-20612	142,546	-
93.855	COLUMBIA UNIVERSITY	3 (GG014746-10)	11,848	-
93.855	COLUMBIA UNIVERSITY	11(GG014746-22)	84,371	-
93.855	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	1560 BYB 252	182,589	-
93.855	FRED HUTCHINSON CANCER RESEARCH CENTER	1110383	198,864	-
93.855	INTEGRATED BIOTHERAPEUTICS INC	AI155309	42,196	-
93.855	DAHLIA BIOSCIENCES INC	2	85,160	-
93.855	UNIVERSITY OF SOUTHERN CALIFORNIA	SCON-00002080	4,364	-
93.855	FRED HUTCHINSON CANCER RESEARCH CENTER	1098581	49,779	-
93.855	ROCHESTER INSTITUTE OF TECHNOLOGY	32664-01	23,194	-
93.855	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	1560 G ZA596	7,814	-
93.855	EMORY UNIVERSITY	A585622	23,179	-
93.855	EMORY UNIVERSITY	A611775	6,775	-
93.855	UNIVERSITY OF COLORADO DENVER	FY22.1117.002	2,016	-
93.855	DUKE UNIVERSITY	2032959	(1,786)	-
93.855	DUKE UNIVERSITY	2032959	(58)	-
93.855	COLUMBIA UNIVERSITY	3 GG011896-65	811	-
93.855	BIOVINC LLC	BV-OMYII-1	289,732	-
93.855	UNIVERSITY OF ALABAMA AT BIRMINGHAM	00522211-015	4,336	-
93.855	UNIVERSITY OF FLORIDA	SUB00002251	13,471	-
93.855	NATIONAL JEWISH HEALTH	20098204	20,956	-
93.855	NATIONAL JEWISH HEALTH	20124003	76,173	-
93.855	FRED HUTCHINSON CANCER RESEARCH CENTER	1029083	(53,769)	-
93.855	JOHNS HOPKINS UNIVERSITY	2004729469	86,460	-
93.855	FRED HUTCHINSON CANCER RESEARCH CENTER	1037695	108,423	-

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Research and Development Program Cluster, continued</b>				
93.855	FRED HUTCHINSON CANCER RESEARCH CENTER	1035296	\$ 1,080,125	\$ -
93.859	UNIVERSITY OF MICHIGAN	SUBK00012248	41,566	-
93.859	UNIVERSITY OF MICHIGAN	SUBK00014170	49,366	-
93.859	SIMPORE INC	MS2.2R44GM137651UR	41,330	-
93.859	SIMPORE INC	MlcroSiMURsub20-21	(300)	-
93.859	HAUPTMAN WOODWARD MEDICAL RESEARCH INSTITUTE	6203-5	600	-
93.859	THOMAS JEFFERSON UNIVERSITY	080-04000-S37301	28,963	-
93.859	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	SA0000673	47,497	-
93.859	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	12310SC	98,704	-
93.859	UNIVERSITY OF NEBRASKA	24-0506-0204-0002	347	-
93.859	HARVARD UNIVERSITY	152564.5121441.0003	337,628	-
93.859	ROCHESTER INSTITUTE OF TECHNOLOGY	31707-01	1,040	-
93.859	UNIVERSITY OF WISCONSIN AT MADISON	1317	33,821	-
93.865	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	2000-G-XC521	134,199	-
93.865	JOHNS HOPKINS UNIVERSITY	2004725638	89,439	-
93.865	JOHNS HOPKINS UNIVERSITY	2004896747	39,744	-
93.865	CORNELL UNIVERSITY	79213-10994	180	-
93.865	PRETEL INC	PRETEL001	113	-
93.865	UNIVERSITY OF FLORIDA	SUB00001522	63,812	-
93.865	PENNSYLVANIA STATE UNIVERSITY	S000313-DHHS	(13,328)	-
93.865	PENNSYLVANIA STATE UNIVERSITY	URMCHD038992	43,725	-
93.865	RUTGERS, THE STATE UNIVERSITY	0132	14,812	-
93.865	HARVARD UNIVERSITY	111268-5107376	17,805	-
93.865	CORNELL UNIVERSITY	82705-11236	32,677	-
93.865	ROCHESTER BUFFALO NEONATAL RESEARCH GROUP	NA	190,796	-
93.866	ALZHEON INC	ALZ-801-AD301	17,555	-
93.866	NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION	STE2196-25	18,336	-
93.866	HARVARD UNIVERSITY	150228.5118708.0043	25,435	-
93.866	BRIGHAM & WOMENS HOSPITAL	FUND 116678	(1,258)	-
93.866	ARIZONA STATE UNIVERSITY	ASUB00000954	239,593	-
93.866	MT SINAI SCHOOL OF MEDICINE	0254-4738-4609	90,303	-
93.866	PENNSYLVANIA STATE UNIVERSITY	S000777-DHHS	70,873	-
93.866	MT SINAI SCHOOL OF MEDICINE	0255-E211-4609	14,067	-
93.866	UNIVERSITY OF NORTH CAROLINA CHAPEL HILL	5120737	26,926	-
93.866	UNIVERSITY OF MINNESOTA	N009029401	24,786	-
93.866	WASHINGTON UNIVERSITY	WU-22-0160	89,176	-
93.866	JOHNS HOPKINS UNIVERSITY	2004494004	10,328	-
93.866	JOHNS HOPKINS UNIVERSITY	2004494004	35,170	-
93.866	OHIO STATE UNIVERSITY	60064632	9,823	-
93.866	MEDICAL UNIVERSITY OF SOUTH CAROLINA	MUSC18-095-8A840	(15,876)	-
93.866	CITY OF HOPE	3000106609	72,766	-
93.866	JOHNS HOPKINS UNIVERSITY	2003392319	114,910	-
93.866	BROWN UNIVERSITY	2032	37,982	-
93.866	BROWN UNIVERSITY	2035	26,057	-
93.866	BROWN UNIVERSITY	975	140	-
93.866	BROWN UNIVERSITY	976	520	-

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards



**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Research and Development Program Cluster, continued</b>				
93.866	YALE UNIVERSITY	GR100664 (CON-80000840)	\$ (407)	\$ -
93.866	STANFORD UNIVERSITY	62722610-229854	22,221	-
93.866	TRANSLATIONAL GENOMICS INSTITUTE	SCHORK-19-06	108,236	-
93.866	UNIVERSITY OF MINNESOTA	N007406701	186,982	-
93.866	UNIVERSITY OF MINNESOTA	N009029401	29,780	-
93.866	DUKE UNIVERSITY	A031295	302,085	-
93.866	UNIVERSITY OF MINNESOTA	N006342601	(23,158)	-
93.866	UNIVERSITY OF SOUTHERN CALIFORNIA	79634921	137,381	-
93.866	UNIVERSITY OF SOUTHERN CALIFORNIA	105715890	183,340	-
93.866	UNIVERSITY OF SOUTHERN CALIFORNIA	120118361	52,419	-
93.866	UNIVERSITY OF SOUTHERN CALIFORNIA	124186217	52,946	-
93.866	UNIVERSITY OF SOUTHERN CALIFORNIA	129136516	(468)	-
93.866	UNIVERSITY OF SOUTHERN CALIFORNIA	129206751	29,183	-
93.866	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	1560BXA683	315	-
93.866	ALBERT EINSTEIN COLLEGE OF MEDICINE	893783	13,912	-
93.866	UNIVERSITY OF PENNSYLVANIA	578076	61,663	-
93.866	BOSTON UNIVERSITY	4500003671	450,770	-
93.866	BOSTON UNIVERSITY	4500003474	34,630	-
93.867	STANFORD UNIVERSITY	62455210-154135	100,468	-
93.867	STANFORD UNIVERSITY	62464606-167717	11,555	-
93.867	STANFORD UNIVERSITY	62611015-177213	73,493	-
93.867	ALDENEX VISION LLC	NA	7,895	-
93.867	JAEB CENTER	C02	(20,096)	-
93.867	UNIVERSITY OF WISCONSIN AT MADISON	1134	12,974	-
93.867	CARNEGIE MELLON UNIVERSITY	1090573-412969	54,102	-
93.867	PENNSYLVANIA STATE UNIVERSITY	URFEY023533(LTF)	(13)	-
93.867	CLEVELAND CLINIC	CCF21375623	79,240	-
	<b>Total National Institutes of Health Pass-Through Awards</b>		<u>24,289,302</u>	<u>-</u>
<b>Food and Drug Administration Pass-Through Awards</b>				
93.103	VIRGINIA COMMONWEALTH UNIVERSITY	FP00009255SA006	\$ 126,402	\$ -
93.103	UNIVERSITY OF KANSAS MEDICAL CENTER	R01FD004809	2,691	-
	<b>Total Food and Drug Administration Pass-Through Awards</b>		<u>129,093</u>	<u>-</u>
<b>Health Resources and Services Administration Pass-Through Awards</b>				
93.110	ORGANIZATION OF TERATOLOGY INFORMATION SPECIALISTS	NA	71,904	37,080
93.877	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	2000 G YC806	271,111	-
	<b>Total Health Resources and Services Administration Pass-Through Awards</b>		<u>343,015</u>	<u>37,080</u>

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Research and Development Program Cluster, continued</b>				
<b>Centers for Disease Control and Prevention Pass-Through Awards</b>				
93.RD	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	12556SC	\$ 27,372	\$ -
93.RD	TASK FORCE FOR GLOBAL HEALTH INC	U38OT000216	60,798	-
93.073	UNIVERSITY OF SOUTH CAROLINA	U19DD001218	29,669	-
93.074	HEALTH RESEARCH INC (HRI)	4864-01	17	-
93.317	HEALTH RESEARCH INC (HRI)	3376-08	3,166,228	-
93.317	HEALTH RESEARCH INC (HRI)	3376-09	752,623	-
93.323	HEALTH RESEARCH INC (HRI)	NU50CK000516	29,641	-
93.421	NATIONAL ASSOC OF COUNTY AND CITY HEALTH OFFICIALS	2019-052206	140	-
93.421	AUCD	12/21/8805	36,234	-
93.917	HEALTH RESEARCH INC (HRI)	5107-04	33,371	-
93.917	COVID 19 - HEALTH RESEARCH INC (HRI)	X0700025	290,885	-
	<b>Total Centers for Disease Control and Prevention Pass-Through Awards</b>		<u>4,426,978</u>	<u>-</u>
<b>Administration for Community Living (ACL) Pass-Through Awards</b>				
93.631	AMERICAN ACADEMY OF DEVELOPMENTAL MEDICINE AND DENTISTRY	309451	17,784	-
	<b>Total Administration for Community Living (ACL) Pass-Through Awards</b>		<u>17,784</u>	<u>-</u>
<b>Administration for Children and Families Pass-Through Awards</b>				
93.093	ACTION FOR A BETTER COMMUNITY	NA	267	-
93.093	ACTION FOR A BETTER COMMUNITY	HPOG 2015-01	15,300	-
	<b>Total Administration for Children and Families Pass-Through Awards</b>		<u>15,567</u>	<u>-</u>
	<b>Total U.S. Department of Health and Human Services Pass-Through Awards</b>		<u>29,681,301</u>	<u>37,080</u>
	<b>Total U.S. Department of Health and Human Services Awards</b>		<u>215,773,032</u>	<u>20,747,038</u>
<b>Total Research and Development Program Cluster</b>			<u>\$ 343,758,684</u>	<u>\$ 28,293,076</u>
<b>Economic Development Cluster:</b>				
<b>U.S. Department of Commerce Awards</b>				
<b>U.S. Department of Commerce Direct Awards</b>				
11.303	ECONOMIC DEVELOPMENT TECHNICAL ASSISTANCE		\$ 44,158	-
11.307	ECONOMIC ADJUSTMENT ASSISTANCE		280,904	-
	<b>Total U.S. Department of Commerce Direct Awards</b>		<u>325,062</u>	<u>-</u>
	<b>Total U.S. Department of Commerce Awards</b>		<u>325,062</u>	<u>-</u>
<b>Total Economic Development Cluster</b>			<u>\$ 325,062</u>	<u>\$ -</u>

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Highway Safety Cluster:</b>			
<b>U.S. Department of Transportation Awards</b>			
<b>U.S. Department of Transportation Pass-Through Awards</b>			
20.600 NEW YORK STATE GOVERNOR'S TRAFFIC	CPS-2017-UR	\$ (113)	\$ -
20.600 NEW YORK STATE GOVERNOR'S TRAFFIC	C002543	12,414	-
20.600 NEW YORK STATE GOVERNOR'S TRAFFIC	SA00001929	479	-
20.600 NEW YORK STATE GOVERNOR'S TRAFFIC	C002547	52,566	-
20.600 NEW YORK STATE GOVERNOR'S TRAFFIC	SA00002053	2,227	-
<b>Total U.S. Department of Transportation Pass-Through Awards</b>		<u>67,573</u>	<u>-</u>
<b>Total Highway Safety Cluster</b>		<u>\$ 67,573</u>	<u>\$ -</u>
<b>Trio Cluster:</b>			
<b>U.S. Department of Education Awards</b>			
<b>U.S. Department of Education Direct Awards</b>			
84.042A TRIO - STUDENT SUPPORT SERVICES		\$ 316,708	\$ -
84.044 TRIO - TALENT SEARCH		209,741	-
84.047 TRIO - UPWARD BOUND		709,645	-
84.217A TRIO - MCNAIR POST BACCALAUREATE ACHIEVEMENT		202,219	-
<b>Total U.S. Department of Education Direct Awards</b>		<u>1,438,313</u>	<u>-</u>
<b>Total Trio Cluster</b>		<u>\$ 1,438,313</u>	<u>\$ -</u>
<b>Aging Cluster:</b>			
<b>U.S. Department of Health and Human Services Awards</b>			
<b>U.S. Department of Health and Human Services Pass Through Awards</b>			
93.045 COVID 19 - MONROE COUNTY OFFICE OF THE AGING	NA	\$ 1,058,196	\$ -
93.045 COVID 19 - NEW YORK STATE OFFICE FOR THE AGING	NA	317,140	-
93.053 NEW YORK STATE WELLNESS IN NUTRITION PROGRAM	NA	7,614	-
<b>Total U.S. Department of Health and Human Services Pass-Through Awards</b>		<u>1,382,950</u>	<u>-</u>
<b>Total Aging Cluster</b>		<u>\$ 1,382,950</u>	<u>\$ -</u>
<b>Other Awards:</b>			
<b>U.S. Department of Housing and Urban Development</b>			
<b>U.S. Department of Housing and Urban Development Pass-Through Awards</b>			
14.906 SILENT SPRING INSTITUTE	7507-URMC-Y1	\$ 82,723	\$ -
<b>Total U.S. Department of Housing and Urban Development Pass-Through Awards</b>		<u>\$ 82,723</u>	<u>\$ -</u>

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Other awards, continued</b>				
<b>U.S. Department of the Interior Awards</b>				
<b>U.S. Department of the Interior Direct Awards</b>				
15.954	NATIONAL PARK SERVICE CONSERVATION, PROTECTION, OUTREACH, AND EDUCATION		\$ 3,449	\$ -
	<b>Total U.S. Department of the Interior Direct Awards</b>		<u>3,449</u>	<u>-</u>
<b>Federal Communications Commission</b>				
<b>Federal Communications Commission Direct Awards</b>				
32.006	COVID 19 - TELEHEALTH PROGRAM		635,000	-
	<b>Total Federal Communications Commission Direct Awards</b>		<u>635,000</u>	<u>-</u>
<b>National Foundation on the Arts and Humanities Awards</b>				
<b>National Foundation on the Arts and Humanities Direct Awards</b>				
45.024	PROMOTION OF THE ARTS, GRANTS TO ORGANIZATIONS AND INDIVIDUALS		88,066	-
45.161	PROMOTION OF THE HUMANITIES RESEARCH		47,607	-
45.162	PROMOTION OF THE HUMANITIES TEACHING AND LEARNING RESOURCES AND CURRICULUM DEV		299	-
45.163	PROMOTION OF THE HUMANITIES PROFESSIONAL DEVELOPMENT		(1,031)	-
45.169	PROMOTION OF THE HUMANITIES OFFICE OF DIGITAL HUMANITIES		29,869	-
45.301	MUSEUMS FOR AMERICA		90,648	-
45.313	LAURA BUSH 21ST CENTURY LIBRARIAN PROGRAM		45,992	-
	<b>Total National Foundation on the Arts and Humanities Direct Awards</b>		<u>301,450</u>	<u>-</u>
<b>U.S. Department of Veterans Affairs Awards</b>				
<b>U.S. Department of Veterans Affairs Direct Awards</b>				
64.U01	CONTRACT - VA240-17-D-0096		(5,026)	-
64.U02	CONTRACT - VA240-17-D-0096		51,443	-
64.U03	CONTRACT - VA240-17-D-0096		23,226	-
	<b>Total U.S. Department of Veterans Affairs Direct Awards</b>		<u>69,643</u>	<u>-</u>
<b>U. S. Department of Education Awards</b>				
84.200	GRADUATE ASSISTANCE IN AREAS OF NATIONAL NEED		19,136	-
84.407	TRANSITION PROGRAMS FOR STUDENTS WITH INTELLECTUAL DISABILITIES INTO HIGHER EDUCATION		19,756	1,199
84.324A	THE MAY INSTITUTE	R324A200154	229,419	-
84.367D	NATIONAL WRITING PROJECT		3,501	-
84.425E	COVID 19 - EMERGENCY RELIEF FUND - STUDENT		9,289,389	-
84.425F	COVID 19 - EMERGENCY RELIEF FUND - INSTITUTIONAL		7,484,242	-
	<b>Total Assistance Listing 84.425</b>		<u>16,773,631</u>	<u>-</u>
	<b>Total U. S. Department of Education Direct Awards</b>		<u>16,816,024</u>	<u>1,199</u>
	<b>Total U. S. Department of Education Pass-Through Awards</b>		<u>229,419</u>	<u>-</u>
	<b>Total U. S. Department of Education Awards</b>		<u>17,045,443</u>	<u>1,199</u>

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

**University of Rochester and Related Entities**  
**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2022**

Assistance Listing Number	Description	Pass-Through Entity Award Numbers	Federal Expenditures	Subrecipient Expenditures
<b>Other awards, continued</b>				
<b>U. S. Department of Health and Human Services Awards (HRSA)</b>				
93.110	MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS		\$ 564,756	\$ -
93.247	ADVANCED NURSING EDUCATION WORKFORCE GRANT PROGRAM		282,522	-
93.498	COVID 19 - PROVIDER RELIEF FUND AND AMERICAN RESCUE PLAN (ARP) DISTRIBUTION		121,005,686	-
93.632	UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOP DISABILITIES, EDUCATION, RESEARCH AND SERVICE		651,125	-
93.732	MENTAL AND BEHAVIORAL HEALTH EDUCATION TRAINING GRANTS		185,686	-
93.834	CAPACITY BUILDING ASSISTANCE (CBA) FOR HIGH-IMPACT HIV PREVENTION		1,130,290	-
93.834	CICATELLI ASSOCIATES INC	NA	41,512	-
	<b>Total Assistance Listing 93.834</b>		<u>1,171,802</u>	<u>-</u>
93.889	NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	NA	242,222	-
93.889	NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	NA	40,000	-
93.889	NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	NA	41,000	-
93.889	NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	NA	40,000	-
93.889	NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	NA	40,000	-
93.889	NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	NA	40,000	-
	<b>Total Assistance Listing 93.889</b>		<u>443,222</u>	<u>-</u>
93.939	HIV PREVENTION ACTIVITIES, NON-GOVERNMENTAL ORGANIZATION BASED		(22,354)	-
93.969	COVID 19 - INTERNATIONAL RESEARCH AND RESEARCH TRAINING		906,802	346,218
93.994	NEW YORK STATE DEPARTMENT OF HEALTH	DOH01-C34857GG-3450000	278,003	-
93.994	NEW YORK STATE DEPARTMENT OF HEALTH	DOH01-C32369GG-3450000	41,433	-
93.994	NEW YORK STATE DEPARTMENT OF HEALTH	DOH01-C34857GG-3450000	118,195	-
	<b>Total Assistance Listing 93.994</b>		<u>437,631</u>	<u>-</u>
	<b>Total U. S. Department of Health and Human Services Direct Awards</b>		<u>124,704,513</u>	<u>346,218</u>
	<b>Total U. S. Department of Health and Human Services Pass-Through Awards</b>		<u>922,365</u>	<u>-</u>
	<b>Total U. S. Department of Health and Human Services Awards</b>		<u>125,626,878</u>	<u>346,218</u>
<b>Corporation for National and Community Service Awards</b>				
<b>Corporation for National and Community Service Direct Awards</b>				
94.013	VOLUNTEERS IN SERVICE TO AMERICA		45,525	-
94.027	AMERICORPS VISTA RECRUITMENT SUPPORT		(1,251)	-
	<b>Total Corporation for National and Community Service Direct Awards</b>		<u>44,274</u>	<u>-</u>
<b>United States Agency for International Development Pass-Through Awards</b>				
98.001	DISCOVERING DEAF WORLDS INC	NA	13,124	-
	<b>Total United States Agency for International Development Pass-Through Awards</b>		<u>13,124</u>	<u>-</u>
<b>Total Other Awards</b>			<u>\$ 143,821,984</u>	<u>\$ 347,417</u>
<b>Total Federal Award Expenditures</b>			<u>\$ 560,568,697</u>	<u>\$ 28,640,493</u>

The accompanying notes are an integral part of the Schedule of Expenditures of Federal Awards

# University of Rochester and Related Entities

## Notes to Schedule of Expenditures of Federal Awards

### Year Ended June 30, 2022

---

#### 1. Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the "Schedule") summarizes the expenditures of the University of Rochester and its related entities (the "University") under programs of the federal government for the year ended June 30, 2022. The information in the Schedule is presented on the accrual basis of accounting, which is in accordance with the Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Because the Schedule presents only the federal award activity of the University, it is not intended to and does not present the financial position, changes in net assets and cash flows of the University.

For purposes of the Schedule, federal awards include all grants, contracts and similar agreements entered into directly between the University and agencies and departments of the federal government and all sub-awards to the University by nonfederal organizations pursuant to federal grants, contracts and similar agreements.

Negative numbers in the Schedule represent adjustments to amounts reported in prior years in the normal course of business. Assistance listing numbers and pass-through numbers are provided when available.

#### 2. Facilities and Administrative Cost Rates

The University had predetermined facilities and administrative cost rates for the year ended June 30, 2022 under a rate agreement with the Department of Health and Human Services, the University's federal cognizant agency. The base rate for on-campus research was 54.0% for fiscal 2022. The base rate for off-campus research was 27.0% for fiscal 2022. The University does not utilize the 10% de minimis cost rate described in section 200.414 of Uniform Guidance.

#### 3. Loan Programs

The Federal Perkins Loan Program and the Federal Nursing Student Loan Program are administered directly by the University and balances and transactions relating to these programs are included in the University's consolidated financial statements. The amount of Federal Perkins loans and Federal Nursing Student loans outstanding at June 30, 2022 totaled \$5,377,526 and \$759,429, respectively. Loans outstanding at the beginning of the year and loans made during the year are included in the federal expenditures presented in the Schedule.

#### 4. CARES Act Provider Relief Funds

The Schedule includes grant activity related to the Department of Health and Human Services ("HHS") Provider Relief Fund and American Rescue Plan (ARP) Distribution Assistance Listing Number 93.498. As required based on guidance in the 2022 OMB Compliance Supplement, the Schedule includes all Period 2 funds received between July 1, 2020 and December 31, 2020 and expended by December 31, 2021 and Period 3 funds received between January 1, 2021 to June 30, 2021 and expended by June 30, 2022 as reported to HRSA via the Provider Relief Funding Reporting Portal.

The Schedule thus includes \$121,005,686 of reportable Provider Relief Payments which includes \$19,185,954 of direct expenditures and \$101,819,732 in lost revenue. Given the timing covered by Periods 2 and 3, certain expenses were reflected in the University's fiscal year 2021 financial statements. Additionally, lost revenue does not represent an expenditure in the University's financial statements and thus is a reconciling item between the federal expenses in the University's financial statements and the amount included on the Schedule.

**Part II – Reports on Internal Controls and Compliance**



**Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance  
and Other Matters Based on an Audit of Financial Statements Performed in Accordance with  
*Government Auditing Standards***

To the Board of Trustees of the University of Rochester

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of the University of Rochester and its related entities (the "University"), which comprise the consolidated balance sheet as of June 30, 2022, and the related consolidated statements of activities and of cash flows for the year then ended, including the related notes (collectively referred to as the "consolidated financial statements"), and have issued our report thereon dated October 26, 2022.

**Report on Internal Control Over Financial Reporting**

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.





### **Report on Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

### **Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

*PricewaterhouseCoopers LLP*

Fairport, New York  
October 26, 2022



## **Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance**

To the Board of Trustees of the University of Rochester

### **Report on Compliance for Each Major Federal Program**

#### ***Opinion on Each Major Federal Program***

We have audited the University of Rochester and its related entities' (the "University") compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended June 30, 2022. The University's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the University complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2022.

#### ***Basis for Opinion on Each Major Federal Program***

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (US GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the University's compliance with the compliance requirements referred to above.

#### ***Responsibilities of Management for Compliance***

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the University's federal programs.



### ***Auditors' Responsibilities for the Audit of Compliance***

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the University's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the University's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the University's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the University's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

### **Report on Internal Control Over Compliance**

*A deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material



weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

*PricewaterhouseCoopers LLP*

Fairport, New York  
March 31, 2023

**Part III – Audit Findings and Questioned Costs**

**University of Rochester and Related Entities**  
**Schedule of Findings and Questioned Costs**  
**Year Ended June 30, 2022**

---

**Section I - Summary of Auditors' Results**

**Financial Statements**

Type of auditors' report issued: Unmodified opinion

Internal control over financial reporting:

Material weakness(es) identified? \_\_\_\_\_ Yes      X   No

Significant deficiency(ies) identified that are not considered to be material weaknesses? \_\_\_\_\_ Yes      X   None reported

Noncompliance material to financial statements noted? \_\_\_\_\_ Yes      X   No

**Federal Awards**

Internal control over major programs:

Material weakness(es) identified? \_\_\_\_\_ Yes      X   No

Significant deficiency(ies) identified that are not considered to be material weaknesses? \_\_\_\_\_ Yes      X   None reported

Type of auditor's report issued on compliance for major programs: Unmodified opinion

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)? \_\_\_\_\_ Yes      X   No

Identification of major programs:

<b>Assistance Listing Number(s)</b>	<b>Name of Federal Program or Cluster</b>
93.498	COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Distribution
84.425E	COVID-19 Education Stabilization Fund - Student
84.425F	COVID-19 Education Stabilization Fund – Institutional
Various	Research & Development Cluster
Various	TRIO Cluster

Dollar threshold used to distinguish between Type A and Type B programs: \$3,000,000

Auditee qualified as low-risk auditee?   X   Yes    \_\_\_\_\_ No

**University of Rochester and Related Entities**  
**Schedule of Findings and Questioned Costs**  
**Year Ended June 30, 2022**

---

**Section II – Financial Statement Findings**

None noted in the current year.

**Section III – Federal Award Findings and Questioned Costs**

None noted in the current year.

# University of Rochester and Related Entities

## Summary Schedule of Prior Audit Findings

### Year Ended June 30, 2022

---

#### **Section IV – Summary Schedule of Prior Audit Findings**

**2021-001:** (A) (B) Unallowed COVID-19 expenditures reported within the Health Resources Services Administration (HRSA) Provider Relief Fund Portal

**Program:** COVID-19 - Provider Relief Fund (PRF) and American Rescue Plan (ARP) Distribution

**Assistance Listing Number:** 93.498

**Agency:** Department of Health and Human Services (HHS)

**Award Year:** 1/1/2020-6/30/2021

**Award Number:** Not available

#### **Condition**

The University of Rochester and Related Entities had 10 Period 1 submissions into the HRSA portal. Period 1 reporting was completed by the following entities: 1. University of Rochester, 2. UR Medicine Home Care, Certified Services, Inc., 3. St. James Hospital, 4. The Frederick Ferris Thompson Hospital, 5. MM Ewing Continuing Care Center, 6. Nicholas H. Noyes Memorial Hospital, 7. Memorial Hospital of William F and Gertrude F Jones Inc. 8. The Highlands Living Center Inc., 9. Highland Hospital of Rochester, and 10. Meadows at Westfall, Inc.

From the detailed listing of expenses across the Period 1 HRSA submissions, PwC performed allowability testing of the “Unreimbursed Expenses Attributable to Coronavirus” in accordance with the Department of Health and Human Services (HHS) terms and conditions. Certain COVID-19 expenditures were either overstated, unallowable expenditures, or (understated). There were also incremental COVID- 19 expenditures not reported, in the Period 1 HRSA submissions by entity, by quarter and in total on a consolidated basis across the organization.

#### **Status**

Pursuant to the HRSA’s updated guidance, the University of Rochester and Related Entities will make lost revenue adjustments in reporting period 4 for the overstated expenses identified in our single audit for the year ended June 30, 2021 (identified above). Additionally, as a result of the findings in our single audit for the year ended June 30, 2021, the University issued updated guidance effective December 2022 regarding tracking and reviewing COVID-19 expenditures and a formal process for the review of HRSA portal submissions prior to submission to the HRSA.



# University of Rochester and Related Entities

## Summary Schedule of Prior Audit Findings

### Year Ended June 30, 2022

---

**2021-002:** (L) Reporting of Unreimbursed Expenses Attributable to Coronavirus and Lost Revenues within the Health Resources Services Administration (HRSA) Provider Relief Fund Portal

**Program:** COVID-19 - Provider Relief Fund (PRF) and American Rescue Plan (ARP) Distribution

**Assistance Listing Number:** 93.498

**Agency:** Department of Health and Human Services (HHS)

**Award Year:** 1/1/2020-6/30/2021

**Award Number:** Not available

The following were identified for the Period 1 HRSA portal submissions:

- Finger Lakes Visiting Nurse Service (FLVNS) ceased operating and transferred service of all patients to UR Medicine Home Care, Certified Services, Inc. (URHC) in November 2019. FLVNS ultimately merged into URHC and ceased to exist in November 2020. FLVNS received PRF payments based on their TIN's Medicare reimbursement for the previous year. For the Period 1 submission, URHC allocated a portion of its total expenses and lost revenue to FLVNS based on the ratio of former FLVNS patients served by URHC to total patients served by URHC in 2020. As a result, FLVNS reported expenses and lost revenue when FLVNS did not have any operating activities in 2020.

FLVNS Period 1 reporting should have shown a transfer to URHC, as allowed under the HHS terms and conditions, with URHC reporting total expenses and lost revenue on its Phase 1 submission. The amount reported on the FLVNS Period 1 HHS report erroneously was \$322,723.

- University of Rochester management identified 5 equipment records submitted for Period 1 reporting that were later discovered to have also been previously reimbursed by other grants. The 5 equipment records submitted on both Period 1 reporting to HRSA and other grants totaled \$87,265.
- Highland Hospital of Rochester management identified nursing agency expenditures that were not appropriately captured in the Period 1 reporting's quarterly reporting. This resulted in an overstatement of nursing agency costs in Quarter 2 (April – June 2021). However, in totality Highland Hospital of Rochester understated these COVID-19 expenditures.
- At our request, Nicholas H. Noyes Memorial Hospital management assessed their reporting of COVID-19 lab tests within the Period 1 reporting to HRSA. As a result of their review, management identified that they overstated COVID-19 lab tests in Quarter 1 (January – March 2020) by \$930 and in Quarter 2 (April – June 2020) by \$13,346. However, underreport the full expenditures of COVID-19 lab tests in Period 1 reporting by \$25,506 if assessing across all allowable quarters from January 2020 – June 2021.

#### Status

With respect to the issues identified above, the University and Related Entities completed the corrective action noted in Management's Corrective Action Plan for the single audit for the year ended June 30, 2021. Further, as a result of the findings in our single audit for the year ended June 30, 2021, the University issued updated guidance effective December 2022 regarding tracking and reviewing COVID-19 expenditures and a formal process for the review of HRSA portal submissions prior to submission to the HRSA.